CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | neuromuscular agent |
|
Accession: | CHEBI:51372
|
browse the term
|
Definition: | A drug used for its actions on skeletal muscle. |
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases activity |
ISO |
glaucine results in increased activity of ABCB1 protein |
CTD |
PMID:23273999 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases chemical synthesis increases glucuronidation multiple interactions increases abundance |
ISO |
CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam CYP3A4 protein results in increased glucuronidation of 1-hydroxymethylmidazolam [[3-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[5-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[6-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[6-methylflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[7-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[alpha-naphthoflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[artemetin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[beta-Naphthoflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[chrysin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[eupatilin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[flavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[galangin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[nobiletin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[sinensetin analog results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[sinensetin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[tangeretin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [CYP3A4 protein results in increased glucuronidation of 1-hydroxymethylmidazolam] which results in increased abundance of 1-hydroxymethylmidazolam glucuronide; [CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased abundance of 1-hydroxymethylmidazolam; [CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [Ketoconazole results in decreased activity of CYP3A4 protein] which results in decreased chemical synthesis of 1-hydroxymethylmidazolam; [L 754394 results in decreased activity of CYP3A4 protein] which results in decreased chemical synthesis of 1-hydroxymethylmidazolam; acacetin promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Apigenin promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 1-hydroxymethylmidazolam]; diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; flavanone promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; flavone promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; galangin promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased abundance of 1-hydroxymethylmidazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Luteolin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Verapamil inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam] |
CTD |
PMID:10997946 PMID:12401345 PMID:12695342 PMID:18191104 PMID:20233841 PMID:21053930 PMID:21915887 PMID:23850985 PMID:26958860 PMID:27485346 PMID:30087611 PMID:31756459 PMID:34189909 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases chemical synthesis multiple interactions |
ISO |
CYP3A5 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam [CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; erdafitinib inhibits the reaction [[CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam] |
CTD |
PMID:18191104 PMID:26958860 PMID:34189909 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Tspo |
translocator protein |
affects binding |
EXP |
1-hydroxymethylmidazolam binds to TSPO protein; 1-hydroxymethylmidazolam metabolite binds to TSPO protein |
CTD |
PMID:7603229 |
|
NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[CYP3A4 protein results in increased glucuronidation of 1-hydroxymethylmidazolam] which results in increased abundance of 1-hydroxymethylmidazolam glucuronide |
CTD |
PMID:27485346 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects chemical synthesis |
ISO |
CYP3A4 protein affects the chemical synthesis of 3-hydroxyquinidine |
CTD |
PMID:15896247 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases chemical synthesis multiple interactions |
ISO |
CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam [CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased abundance of 4-hydroxymidazolam; [CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam; acacetin inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; Apigenin inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 4-hydroxymidazolam]; diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; flavanone inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; flavone inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; galangin inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Luteolin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:12695342 PMID:18191104 PMID:21053930 PMID:27485346 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases chemical synthesis multiple interactions |
ISO |
CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam diosmetin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Luteolin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
|
G |
Arhgef17 |
Rho guanine nucleotide exchange factor 17 |
multiple interactions |
ISO |
[8-bromocyclic GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein |
CTD |
PMID:23195829 |
|
NCBI chr 1:155,230,607...155,290,163
Ensembl chr 1:155,233,168...155,290,498
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]; KT 5823 inhibits the reaction [8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]] |
CTD |
PMID:9388267 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
increases expression multiple interactions |
ISO |
8-bromocyclic GMP results in increased expression of COX4I1 protein tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of COX4I1 protein] |
CTD |
PMID:24041027 |
|
NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
increases expression |
ISO |
8-bromocyclic GMP results in increased expression of DUSP10 mRNA; 8-bromocyclic GMP results in increased expression of DUSP10 protein |
CTD |
PMID:29165873 |
|
NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP ISO |
8-bromocyclic GMP inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein] 8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of EDN1 mRNA]; 8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of EDN1 protein] |
CTD |
PMID:16023617 PMID:29165873 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn3 |
endothelin 3 |
multiple interactions |
EXP |
8-bromocyclic GMP inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein] |
CTD |
PMID:16023617 |
|
NCBI chr 3:163,562,307...163,586,636
Ensembl chr 3:163,562,520...163,585,093
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
EXP |
8-bromocyclic GMP inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]; 8-bromocyclic GMP inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein] |
CTD |
PMID:16023617 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of HIF1A mRNA]; 8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of HIF1A protein] |
CTD |
PMID:29165873 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
8-bromocyclic GMP results in increased expression of HMOX1 mRNA; 8-bromocyclic GMP results in increased expression of HMOX1 protein |
CTD |
PMID:24041027 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
8-bromocyclic GMP promotes the reaction [IL1B protein results in increased abundance of Nitrites]; Dipyridamole promotes the reaction [8-bromocyclic GMP promotes the reaction [IL1B protein results in increased abundance of Nitrites]] |
CTD |
PMID:8904084 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
increases expression multiple interactions |
ISO |
8-bromocyclic GMP results in increased expression of IL4 mRNA Cyclosporine inhibits the reaction [8-bromocyclic GMP results in increased expression of IL4 mRNA] |
CTD |
PMID:16533816 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
ISO |
8-bromocyclic GMP results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:17828804 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
ISO |
8-bromocyclic GMP results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:17828804 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases phosphorylation |
ISO |
8-bromocyclic GMP results in decreased phosphorylation of MYC protein |
CTD |
PMID:17828804 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ndufb8 |
NADH:ubiquinone oxidoreductase subunit B8 |
increases expression multiple interactions |
ISO |
8-bromocyclic GMP results in increased expression of NDUFB8 protein tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of NDUFB8 protein] |
CTD |
PMID:24041027 |
|
NCBI chr 1:243,408,656...243,413,715
Ensembl chr 1:243,408,619...243,413,817
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
affects localization |
ISO |
8-bromocyclic GMP affects the localization of NFATC1 protein |
CTD |
PMID:16533816 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
increases expression multiple interactions |
ISO |
8-bromocyclic GMP results in increased expression of NRF1 mRNA tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of NRF1 mRNA] |
CTD |
PMID:24041027 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Pde5a |
phosphodiesterase 5A |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with 8-bromocyclic GMP] results in increased expression of PDE5A protein; [1-Methyl-3-isobutylxanthine co-treated with 8-bromocyclic GMP] results in increased expression of PDE5A protein modified form |
CTD |
PMID:20613715 |
|
NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
ISO |
8-bromocyclic GMP results in increased expression of PPARGC1A mRNA tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:24041027 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
increases expression multiple interactions |
EXP ISO |
8-bromocyclic GMP results in increased expression of PRKG1 protein [8-bromocyclic GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein |
CTD |
PMID:12620371 PMID:23195829 |
|
NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Scnn1b |
sodium channel epithelial 1 subunit beta |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with 8-bromocyclic GMP] results in increased expression of SCNN1B protein |
CTD |
PMID:20613715 |
|
NCBI chr 1:176,430,063...176,484,451
Ensembl chr 1:176,430,103...176,484,451
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
EXP |
8-bromocyclic GMP results in increased expression of SOD2 mRNA; 8-bromocyclic GMP results in increased expression of SOD2 protein |
CTD |
PMID:14996425 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]; Dinitrochlorobenzene inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; KT 5823 inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]] |
CTD |
PMID:20453393 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Srf |
serum response factor |
multiple interactions |
ISO |
[8-bromocyclic GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein |
CTD |
PMID:23195829 |
|
NCBI chr 9:14,426,453...14,435,734
Ensembl chr 9:14,426,472...14,435,733
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression multiple interactions |
ISO |
8-bromocyclic GMP results in increased expression of TFAM mRNA tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of TFAM mRNA] |
CTD |
PMID:24041027 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
8-bromocyclic GMP inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]; 8-bromocyclic GMP inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein] |
CTD |
PMID:16023617 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]; KT 5823 inhibits the reaction [8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]] |
CTD |
PMID:9388267 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
EXP |
8-bromocyclic GMP results in increased expression of TP53 protein |
CTD |
PMID:9888876 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
multiple interactions increases phosphorylation |
EXP ISO |
8-bromocyclic GMP inhibits the reaction [1-oleoyl-2-acetylglycerol results in increased activity of TRPC6 protein] 8-bromocyclic GMP results in increased phosphorylation of TRPC6 protein KT 5823 inhibits the reaction [8-bromocyclic GMP results in increased phosphorylation of TRPC6 protein] |
CTD |
PMID:20177073 |
|
NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
EXP |
8-bromocyclic GMP inhibits the reaction [Glucose results in decreased expression of TXN1 protein] |
CTD |
PMID:20453393 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Uqcrc1 |
ubiquinol-cytochrome c reductase core protein 1 |
multiple interactions increases expression |
ISO |
tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of UQCRC1 protein] |
CTD |
PMID:24041027 |
|
NCBI chr 8:109,589,735...109,601,481
Ensembl chr 8:109,589,706...109,601,480
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
decreases expression |
ISO |
8-bromocyclic GMP results in decreased expression of VCAM1 protein |
CTD |
PMID:17828804 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
8-bromocyclic GMP results in decreased expression of VEGFA protein |
CTD |
PMID:17828804 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
multiple interactions affects binding |
ISO |
WIN 62577 inhibits the reaction [Alcuronium binds to CHRM4 protein] |
CTD |
PMID:16709648 |
|
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO |
Alcuronium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Alcuronium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] |
CTD |
PMID:14645658 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
Alcuronium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Alcuronium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] |
CTD |
PMID:14645658 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
|
G |
Capn1 |
calpain 1 |
multiple interactions |
ISO |
[Caffeine co-treated with Alprazolam] promotes the reaction [Calcium results in increased activity of CAPN1 protein] |
CTD |
PMID:19490937 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[Caffeine co-treated with Alprazolam] results in increased cleavage of CASP3 protein |
CTD |
PMID:19490937 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
[Caffeine co-treated with Alprazolam] results in increased secretion of CTSB protein |
CTD |
PMID:19490937 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions affects metabolic processing |
ISO |
CYP3A4 protein binds to and affects the metabolism of Alprazolam CYP3A4 protein affects the metabolism of Alprazolam |
CTD |
PMID:12196913 PMID:15856409 PMID:16042670 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
affects metabolic processing |
EXP |
CYP3A23-3A1 protein affects the metabolism of Alprazolam |
CTD |
PMID:12196913 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases hydroxylation |
ISO |
CYP3A5 protein results in increased hydroxylation of Alprazolam |
CTD |
PMID:15903124 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Il2 |
interleukin 2 |
decreases expression |
ISO |
Alprazolam results in decreased expression of IL2 protein |
CTD |
PMID:1624223 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases secretion |
ISO |
Alprazolam results in increased secretion of LHB protein |
CTD |
PMID:7883836 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with Alprazolam] results in increased activity of PARP1 protein |
CTD |
PMID:19490937 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Plcb1 |
phospholipase C beta 1 |
decreases expression |
EXP |
Alprazolam results in decreased expression of PLCB1 mRNA; Alprazolam results in decreased expression of PLCB1 protein |
CTD |
PMID:12527476 |
|
NCBI chr 3:122,059,988...122,772,896
Ensembl chr 3:122,060,031...122,772,869
|
|
G |
Ppia |
peptidylprolyl isomerase A |
increases hydroxylation |
ISO |
PPIA protein results in increased hydroxylation of Alprazolam |
CTD |
PMID:15806426 |
|
NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Alprazolam inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Trh |
thyrotropin releasing hormone |
multiple interactions |
EXP |
Alprazolam inhibits the reaction [TRH protein modified form binds to TRHR protein] |
CTD |
PMID:2845442 |
|
NCBI chr 4:124,742,111...124,777,094
Ensembl chr 4:124,742,111...124,744,637
|
|
G |
Trhr |
thyrotropin releasing hormone receptor |
multiple interactions |
EXP |
Alprazolam inhibits the reaction [TRH protein modified form binds to TRHR protein] |
CTD |
PMID:2845442 |
|
NCBI chr 7:75,348,672...75,393,310
Ensembl chr 7:75,348,672...75,393,309
|
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
affects binding |
EXP |
alverine binds to HTR1A protein |
CTD |
PMID:11697552 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
alverine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
increases expression |
ISO |
Aminophylline results in increased expression of ALDH18A1 mRNA |
CTD |
PMID:29901742 |
|
NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Aminophylline co-treated with Gemcitabine] results in decreased expression of BCL2 protein |
CTD |
PMID:15645133 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[Aminophylline co-treated with Photosensitizing Agents] promotes the reaction [Benzo(a)pyrene results in increased expression of CAT protein] |
CTD |
PMID:30776357 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Gcg |
glucagon |
increases secretion |
EXP |
Aminophylline results in increased secretion of GCG protein |
CTD |
PMID:1248788 |
|
NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions |
ISO |
[Astemizole binds to and results in decreased activity of HRH1 protein] which affects the susceptibility to Aminophylline |
CTD |
PMID:16129921 |
|
NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Ins1 |
insulin 1 |
increases secretion |
EXP |
Aminophylline results in increased secretion of INS1 protein |
CTD |
PMID:1248788 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
ISO |
Atracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Atracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]] |
CTD |
PMID:16931985 |
|
NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO |
Atracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] |
CTD |
PMID:16931985 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions |
ISO |
Atracurium inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein] |
CTD |
PMID:16931985 |
|
NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
Atracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Atracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] |
CTD |
PMID:16931985 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
Atracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]] |
CTD |
PMID:16931985 |
|
NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Hexb |
hexosaminidase subunit beta |
increases secretion |
ISO |
Atracurium results in increased secretion of HEXB protein |
CTD |
PMID:19758318 |
|
NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases transport |
ISO |
ABCC4 protein results in increased transport of Baclofen |
CTD |
PMID:17939016 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
Baclofen promotes the reaction [Isoproterenol results in increased activity of CFTR protein] |
CTD |
PMID:15151902 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Baclofen inhibits the reaction [Amphetamine affects the phosphorylation of CREB1 protein] |
CTD |
PMID:16983645 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Drd3 |
dopamine receptor D3 |
decreases expression |
EXP |
Baclofen results in decreased expression of DRD3 mRNA |
CTD |
PMID:7878047 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO EXP |
Baclofen inhibits the reaction [Cocaine results in increased expression of FOS protein] |
CTD |
PMID:16710312 PMID:16930414 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
decreases expression multiple interactions |
EXP |
Baclofen results in decreased expression of FSHB protein Baclofen inhibits the reaction [Diethylhexyl Phthalate results in increased expression of FSHB protein] |
CTD |
PMID:29774754 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gabbr1 |
gamma-aminobutyric acid type B receptor subunit 1 |
increases response to substance |
ISO |
GABBR1 results in increased susceptibility to Baclofen |
CTD |
PMID:16990508 PMID:20138995 |
|
NCBI chr20:1,464,534...1,494,114
Ensembl chr20:1,464,534...1,493,994
|
|
G |
Gabbr2 |
gamma-aminobutyric acid type B receptor subunit 2 |
increases response to substance |
ISO |
GABBR2 results in increased susceptibility to Baclofen |
CTD |
PMID:20138995 |
|
NCBI chr 5:60,947,517...61,288,104
Ensembl chr 5:60,947,526...61,288,104
|
|
G |
Kcnj6 |
potassium inwardly-rectifying channel, subfamily J, member 6 |
increases response to substance |
ISO |
KCNJ6 results in increased susceptibility to Baclofen |
CTD |
PMID:12836919 |
|
NCBI chr11:34,061,702...34,308,758
Ensembl chr11:34,061,708...34,308,758
|
|
G |
Lhb |
luteinizing hormone subunit beta |
decreases expression multiple interactions |
EXP |
Baclofen results in decreased expression of LHB protein Baclofen inhibits the reaction [Diethylhexyl Phthalate results in increased expression of LHB protein] |
CTD |
PMID:29774754 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Maob |
monoamine oxidase B |
multiple interactions |
ISO |
Baclofen affects the reaction [MAOB gene mutant form results in decreased susceptibility to Amphetamine] |
CTD |
PMID:16983645 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP |
Baclofen results in increased phosphorylation of MAPK1 protein CGP 56999A inhibits the reaction [Baclofen results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24668805 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
CGP 56999A inhibits the reaction [Baclofen results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24668805 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Pdyn |
prodynorphin |
multiple interactions |
EXP |
Baclofen inhibits the reaction [Amphetamine results in increased expression of PDYN mRNA] |
CTD |
PMID:15033416 PMID:15592348 |
|
NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334
|
|
G |
Penk |
proenkephalin |
multiple interactions |
EXP |
Baclofen inhibits the reaction [Amphetamine results in increased expression of PENK mRNA] |
CTD |
PMID:15033416 PMID:15592348 |
|
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
|
|
G |
Ryr1 |
ryanodine receptor 1 |
multiple interactions |
ISO |
Baclofen inhibits the reaction [A 68930 results in increased expression of RYR1 protein]; Baclofen inhibits the reaction [SK&F 82958 results in increased expression of RYR1 protein] |
CTD |
PMID:22504960 |
|
NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812
|
|
G |
Ryr2 |
ryanodine receptor 2 |
multiple interactions |
ISO |
Baclofen inhibits the reaction [A 68930 results in increased expression of RYR2 protein]; Baclofen inhibits the reaction [SK&F 82958 results in increased expression of RYR2 protein] |
CTD |
PMID:22504960 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
G |
Scg2 |
secretogranin II |
multiple interactions |
EXP |
Baclofen inhibits the reaction [Amphetamine results in increased expression of SCG2 mRNA] |
CTD |
PMID:15033416 PMID:15592348 |
|
NCBI chr 9:80,803,074...80,808,646
Ensembl chr 9:80,803,075...80,821,097
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
Baclofen inhibits the reaction [Amphetamine results in increased expression of TAC1 mRNA] |
CTD |
PMID:15033416 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion |
ISO |
Baclofen results in decreased secretion of TNF protein |
CTD |
PMID:20201957 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Butylscopolammonium Bromide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions |
ISO |
[CYP2C19 gene polymorphism affects the metabolism of Carisoprodol] which affects the chemical synthesis of Meprobamate; [CYP2C19 protein results in increased metabolism of Carisoprodol] which results in increased chemical synthesis of Meprobamate |
CTD |
PMID:12835613 PMID:22527345 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
ISO |
Bemegride inhibits the reaction [Carisoprodol results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; Carisoprodol binds to and affects the activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein] |
CTD |
PMID:19244096 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
ISO |
Bemegride inhibits the reaction [Carisoprodol results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; Carisoprodol binds to and affects the activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein] |
CTD |
PMID:19244096 |
|
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
ISO |
Bemegride inhibits the reaction [Carisoprodol results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; Carisoprodol binds to and affects the activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein] |
CTD |
PMID:19244096 |
|
NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
chlorphenesin carbamate inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
CYB5A protein promotes the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone] |
CTD |
PMID:15728263 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
affects metabolic processing |
EXP |
CYP1A1 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:15231049 PMID:15879494 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects metabolic processing increases hydroxylation |
ISO EXP |
CYP1A2 protein affects the metabolism of Chlorzoxazone CYP1A2 protein results in increased hydroxylation of Chlorzoxazone |
CTD |
PMID:11911841 PMID:14586387 PMID:15879494 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Chlorzoxazone results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2B1 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:15879494 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
affects metabolic processing |
EXP |
CYP2C11 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:15879494 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c13 |
cytochrome P450, family 2, subfamily c, polypeptide 13 |
affects metabolic processing |
EXP |
CYP2C13 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:15879494 |
|
NCBI chr 1:238,786,764...238,867,195
Ensembl chr 1:238,786,765...238,867,191
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
affects metabolic processing |
EXP |
CYP2C6V1 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:15879494 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects hydroxylation increases metabolic processing increases hydroxylation multiple interactions affects metabolic processing increases oxidation |
ISO EXP |
CYP2E1 protein affects the hydroxylation of Chlorzoxazone CYP2E1 protein results in increased metabolism of Chlorzoxazone CYP2E1 protein results in increased hydroxylation of Chlorzoxazone [CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased abundance of 6-hydroxychlorzoxazone; [CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone; Resveratrol inhibits the reaction [CYP2E1 protein results in increased metabolism of Chlorzoxazone] CYP2E1 mRNA results in increased metabolism of Chlorzoxazone; CYP2E1 protein results in increased metabolism of Chlorzoxazone CYP2E1 protein affects the metabolism of Chlorzoxazone [CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone; Imidazoles inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; Isoquinolines inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; Pyridines inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; Quinolines inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone] CYP2E1 protein results in increased oxidation of Chlorzoxazone [5-bromotryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [5-chlorotryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [5-fluoro-alpha-methyltryptamine results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [5-fluorotryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [5-methyltryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [7-methyltryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [Chlormethiazole results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [Chlorzoxazone results in decreased activity of CYP2E1 protein] which results in decreased degradation of vanoxerine; [CYP2E1 mRNA results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone; [CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone; [indopan analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [indopan results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [Methoxydimethyltryptamines analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [N,N-diallyl-5-methoxytryptamine results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [N,N-diisopropyltryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [Tryptamines analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; Carbaryl inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; chlorfluazuron inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; Chlorpyrifos inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; CYB5A protein promotes the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; cypermethrin inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; Disulfiram inhibits the reaction [[CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone]; Disulfiram inhibits the reaction [CYP2E1 protein results in increased metabolism of Chlorzoxazone]; Fenitrothion inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; fenvalerate inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; Fomepizole inhibits the reaction [CYP2E1 protein results in increased metabolism of Chlorzoxazone]; isoproturon inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; Malathion inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; perfluorooctane sulfonic acid inhibits the reaction [CYP2E1 protein results in increased oxidation of Chlorzoxazone]; phenthoate inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; profenofos inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone] |
CTD |
PMID:7747284 PMID:8558417 PMID:8858968 PMID:9817075 PMID:9825833 PMID:10207612 PMID:10463382 PMID:11502731 PMID:11911841 PMID:12401345 PMID:12433797 PMID:12464242 PMID:12690492 PMID:12818727 PMID:14586387 PMID:15155557 PMID:15205388 PMID:15231049 PMID:15255802 PMID:15327588 PMID:15370959 PMID:15576447 PMID:15618748 PMID:15626586 PMID:15728263 PMID:15802389 PMID:15879494 PMID:16124035 PMID:17565714 PMID:21600194 PMID:21915887 PMID:21964418 PMID:22634058 PMID:23669205 PMID:25956474 PMID:26599973 PMID:26739624 PMID:28438436 PMID:28762043 PMID:29555536 PMID:30503582 PMID:31501917 More...
|
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects metabolic processing |
EXP |
CYP3A2 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:15879494 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases hydroxylation affects metabolic processing |
EXP |
CYP3A23-3A1 protein results in increased hydroxylation of Chlorzoxazone CYP3A23-3A1 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:11911841 PMID:15879494 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects metabolic processing |
EXP |
CYP3A9 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:15879494 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
INS protein inhibits the reaction [stearic acid results in increased hydroxylation of Chlorzoxazone] |
CTD |
PMID:26739624 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Kcnn4 |
potassium calcium-activated channel subfamily N member 4 |
increases activity |
ISO |
Chlorzoxazone results in increased activity of KCNN4 protein |
CTD |
PMID:14985237 |
|
NCBI chr 1:79,956,380...79,974,354
Ensembl chr 1:79,959,322...79,974,340
|
|
G |
Nat2 |
N-acetyltransferase 2 |
affects metabolic processing |
ISO |
NAT2 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:14586387 |
|
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Xdh |
xanthine dehydrogenase |
affects metabolic processing |
ISO |
XDH protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:14586387 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions increases expression |
ISO |
CXCR4 protein inhibits the reaction [cisatracurium results in increased expression of CDH1 protein]; TGFB1 protein inhibits the reaction [cisatracurium results in increased expression of CDH1 protein] |
CTD |
PMID:33617803 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression multiple interactions |
ISO |
cisatracurium results in decreased expression of CDH2 protein CXCR4 protein inhibits the reaction [cisatracurium results in decreased expression of CDH2 protein]; TGFB1 protein inhibits the reaction [cisatracurium results in decreased expression of CDH2 protein] |
CTD |
PMID:33617803 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
ISO |
cisatracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; cisatracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]] |
CTD |
PMID:16931985 |
|
NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO |
cisatracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] |
CTD |
PMID:16931985 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions |
ISO |
cisatracurium inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein] |
CTD |
PMID:16931985 |
|
NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
cisatracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; cisatracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] |
CTD |
PMID:16931985 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
cisatracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]] |
CTD |
PMID:16931985 |
|
NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression decreases expression multiple interactions |
ISO |
cisatracurium results in decreased expression of CXCR4 mRNA; cisatracurium results in decreased expression of CXCR4 protein cisatracurium decreases expression of CXCR4 mRNA and protein in colonic epithelium CXCR4 protein inhibits the reaction [cisatracurium results in decreased expression of CDH2 protein]; CXCR4 protein inhibits the reaction [cisatracurium results in decreased expression of VIM protein]; CXCR4 protein inhibits the reaction [cisatracurium results in increased expression of CDH1 protein]; TGFB1 protein inhibits the reaction [cisatracurium results in decreased expression of CXCR4 protein] |
CTD RGD |
PMID:33617803 PMID:33617803 |
RGD:151893498 |
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases expression |
ISO |
TGFB1 protein inhibits the reaction [cisatracurium results in decreased expression of CDH2 protein]; TGFB1 protein inhibits the reaction [cisatracurium results in decreased expression of CXCR4 protein]; TGFB1 protein inhibits the reaction [cisatracurium results in decreased expression of TGFBR1 protein]; TGFB1 protein inhibits the reaction [cisatracurium results in decreased expression of VIM protein]; TGFB1 protein inhibits the reaction [cisatracurium results in increased expression of CDH1 protein] cisatracurium results in decreased expression of TGFB1 protein |
CTD |
PMID:33617803 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
decreases expression multiple interactions |
ISO |
cisatracurium results in decreased expression of TGFBR1 protein TGFB1 protein inhibits the reaction [cisatracurium results in decreased expression of TGFBR1 protein] |
CTD |
PMID:33617803 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Vim |
vimentin |
decreases expression multiple interactions |
ISO |
cisatracurium results in decreased expression of VIM protein CXCR4 protein inhibits the reaction [cisatracurium results in decreased expression of VIM protein]; TGFB1 protein inhibits the reaction [cisatracurium results in decreased expression of VIM protein] |
CTD |
PMID:33617803 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
clidinium inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
cyclobenzaprine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects transport |
ISO |
ABCG2 protein affects the transport of Dantrolene |
CTD |
PMID:18322075 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
increases expression |
ISO |
Dantrolene results in increased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Atf4 |
activating transcription factor 4 |
decreases expression multiple interactions |
EXP ISO |
Dantrolene results in decreased expression of ATF4 protein Dantrolene affects the reaction [perfluorooctanoic acid results in increased expression of ATF4 protein]; Dantrolene inhibits the reaction [Thapsigargin results in increased expression of ATF4 protein]; Dantrolene promotes the reaction [Thapsigargin results in increased expression of ATF4 mRNA] |
CTD |
PMID:15921666 PMID:32578922 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Halothane results in increased expression of BAX mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
EXP |
Dantrolene results in increased expression of BCL2 protein |
CTD |
PMID:10854250 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Halothane results in increased expression of BCL2L11 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Oxygen deficiency results in increased secretion of BDNF protein] |
CTD |
PMID:16553631 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Capn1 |
calpain 1 |
decreases expression |
EXP |
Dantrolene results in decreased expression of CAPN1 mRNA; Dantrolene results in decreased expression of CAPN1 protein |
CTD |
PMID:11236903 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capn2 |
calpain 2 |
decreases expression |
EXP |
Dantrolene results in decreased expression of CAPN2 mRNA; Dantrolene results in decreased expression of CAPN2 protein |
CTD |
PMID:11236903 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Capn3 |
calpain 3 |
decreases expression |
EXP |
Dantrolene results in decreased expression of CAPN3 mRNA; Dantrolene results in decreased expression of CAPN3 protein |
CTD |
PMID:11236903 |
|
NCBI chr 3:107,407,518...107,457,858
Ensembl chr 3:107,407,850...107,457,858
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
Dantrolene inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein] Dantrolene inhibits the reaction [Indomethacin results in increased activity of CASP3 protein] |
CTD |
PMID:17079870 PMID:23022152 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Indomethacin results in increased activity of CASP9 protein] |
CTD |
PMID:23022152 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
EXP |
Dantrolene results in decreased expression of CCL2 mRNA |
CTD |
PMID:25051504 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
affects expression |
EXP |
Dantrolene affects the expression of CCL5 protein |
CTD |
PMID:25051504 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Halothane results in increased expression of CXCL2 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO EXP |
Dantrolene inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:18493746 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] |
CTD |
PMID:18493746 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
decreases phosphorylation multiple interactions |
EXP ISO |
Dantrolene results in decreased phosphorylation of DDIT3 protein Dantrolene inhibits the reaction [Halothane results in increased expression of DDIT3 mRNA]; Dantrolene promotes the reaction [perfluorooctanoic acid results in increased expression of DDIT3 mRNA]; Dantrolene promotes the reaction [perfluorooctanoic acid results in increased expression of DDIT3 protein] |
CTD |
PMID:15921666 PMID:32578922 PMID:32795494 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Edn1 |
endothelin 1 |
decreases activity |
EXP |
Dantrolene results in decreased activity of EDN1 protein |
CTD |
PMID:12628492 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
decreases phosphorylation |
EXP |
Dantrolene results in decreased phosphorylation of EIF2AK3 protein |
CTD |
PMID:15921666 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
decreases phosphorylation multiple interactions |
EXP ISO |
Dantrolene results in decreased phosphorylation of EIF2S1 protein Dantrolene inhibits the reaction [tributyltin results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:15921666 PMID:23743301 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Halothane results in increased expression of FKBP1A mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Halothane results in increased expression of FKBP1B mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of GFAP protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of GFAP protein] |
CTD |
PMID:21863293 PMID:21879721 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Halothane results in increased expression of GPT protein] |
CTD |
PMID:32795494 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Halothane results in increased expression of HMOX1 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Homer1 |
homer scaffold protein 1 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Halothane results in increased expression of HOMER1 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [tributyltin results in increased expression of HSPA5 protein] |
CTD |
PMID:23743301 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IFNG mRNA] |
CTD |
PMID:22517774 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases response to substance |
ISO |
Dantrolene results in decreased susceptibility to IGF1 protein |
CTD |
PMID:16485066 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf2 |
insulin-like growth factor 2 |
decreases response to substance |
ISO |
Dantrolene results in decreased susceptibility to IGF2 protein |
CTD |
PMID:16485066 |
|
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
|
|
G |
Il10 |
interleukin 10 |
multiple interactions affects expression |
ISO EXP |
Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]] Dantrolene affects the expression of IL10 protein |
CTD |
PMID:17707769 PMID:25051504 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
affects expression multiple interactions |
EXP ISO |
Dantrolene affects the expression of IL1B mRNA Dantrolene inhibits the reaction [Halothane results in increased expression of IL1B mRNA] |
CTD |
PMID:25051504 PMID:32795494 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IL6 mRNA] |
CTD |
PMID:22517774 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Dantrolene results in decreased activity of KCNH2 protein |
CTD |
PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [KCNJ11 protein mutant form results in increased abundance of Calcium] |
CTD |
PMID:17189350 |
|
NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Lep |
leptin |
decreases expression |
EXP |
Dantrolene results in decreased expression of LEP protein |
CTD |
PMID:25051504 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A mRNA]; Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A protein] |
CTD |
PMID:25093688 |
|
NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C mRNA]; Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C protein] |
CTD |
PMID:25093688 |
|
NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [Caffeine results in increased expression of MYH7 mRNA] |
CTD |
PMID:25093688 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of NEFL protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of NEFL protein] |
CTD |
PMID:21863293 PMID:21879721 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nefm |
neurofilament medium chain |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of NEFM protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of NEFM protein] |
CTD |
PMID:21863293 PMID:21879721 |
|
NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [Caffeine results in increased expression of NPPA mRNA] |
CTD |
PMID:25093688 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [Caffeine results in increased expression of NPPB mRNA] |
CTD |
PMID:25093688 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Ryr1 |
ryanodine receptor 1 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]]; Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] which results in increased transport of Calcium] |
CTD |
PMID:17707769 |
|
NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812
|
|
G |
Ryr2 |
ryanodine receptor 2 |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [Caffeine promotes the reaction [RYR2 protein results in increased secretion of Calcium]] |
CTD |
PMID:12887973 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Halothane results in increased expression of S100A8 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Halothane results in increased expression of S100A9 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA] |
CTD |
PMID:23183170 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
EXP ISO |
Dantrolene results in decreased expression of TNF protein Dantrolene inhibits the reaction [Halothane results in increased expression of TNF mRNA] |
CTD |
PMID:11236903 PMID:32795494 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Halothane results in increased expression of VCAM1 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vim |
vimentin |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of VIM protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of VIM protein] |
CTD |
PMID:21863293 PMID:21879721 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [perfluorooctanoic acid results in increased expression of XBP1 mRNA alternative form]; Dantrolene inhibits the reaction [Thapsigargin results in increased expression of XBP1 mRNA alternative form] |
CTD |
PMID:32578922 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
multiple interactions |
ISO |
darifenacin binds to and results in decreased activity of CHRM2 protein |
CTD |
PMID:15140916 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
multiple interactions |
ISO |
darifenacin binds to and results in decreased activity of CHRM3 protein |
CTD |
PMID:11488427 PMID:15140916 |
|
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
darifenacin results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
Bche |
butyrylcholinesterase |
decreases activity |
ISO |
decamethonium results in decreased activity of BCHE protein |
CTD |
PMID:31173753 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO |
Carbachol inhibits the reaction [decamethonium binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; decamethonium binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; decamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; decamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] |
CTD |
PMID:14645658 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
Carbachol inhibits the reaction [decamethonium binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; decamethonium binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; decamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; decamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] |
CTD |
PMID:14645658 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Dicyclomine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] |
CTD |
PMID:12511591 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Atoh1 |
atonal bHLH transcription factor 1 |
multiple interactions |
ISO |
Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in increased expression of ATOH1 mRNA] |
CTD |
PMID:23056257 |
|
NCBI chr 4:93,912,068...93,914,163
Ensembl chr 4:93,912,068...93,914,154
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in decreased expression of CCND1 mRNA] |
CTD |
PMID:23056257 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in decreased expression of CDK4 protein] |
CTD |
PMID:15231866 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
EXP |
dihydro-beta-erythroidine affects binding to Chrna2 protein; dihydro-beta-erythroidine inhibits the reaction [epibatidine affects binding to Chrna2 protein] in rat retina |
RGD |
PMID:16129735 |
RGD:2303195 |
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
EXP |
Dihydro-beta-Erythroidine results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein] dihydro-beta-erythroidine affects binding [Epibatidine binds to Chrna3 protein] |
CTD RGD |
PMID:9687574 PMID:16129735 PMID:15016836 |
RGD:2303195, RGD:2303194 |
NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions affects binding |
ISO EXP |
Carbachol inhibits the reaction [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine inhibits the reaction [1-Butanol binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] dihydro-beta-erythroidine affects binding to Chrna4 protein; dihydro-beta-erythroidine inhibits the reaction [epibatidine affects binding to Chrna4 protein] in rat retina dihydro-beta-erythroidine affects binding to Chrna4 protein; dihydro-beta-erythroidine competes with [Epibatidine binds to Chrna4 protein] [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in decreased susceptibility to Nicotine; Dihydro-beta-Erythroidine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in increased expression of CHRNA4 mRNA]; Dihydro-beta-Erythroidine inhibits the reaction [[pozanicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in increased secretion of Acetylcholine]; Dihydro-beta-Erythroidine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine inhibits the reaction [3-(2-(pyrrolidinyl)methoxy)pyridine analog results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] [CHRNA4 protein binds to CHRNB4 protein] which binds to Dihydro-beta-Erythroidine |
CTD RGD |
PMID:9687574 PMID:10945867 PMID:11600638 PMID:12604691 PMID:14645658 PMID:16569710 PMID:16915382 PMID:18385335 PMID:19047205 PMID:20100906 PMID:28555334 PMID:16129735 PMID:15016836 More...
|
RGD:2303195, RGD:2303194 |
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
increases activity multiple interactions affects response to substance |
ISO EXP |
Dihydro-beta-Erythroidine results in increased activity of CHRNA7 protein mutant form Dihydro-beta-Erythroidine affects the reaction [iodo-alpha-bungarotoxin binds to CHRNA7 protein] CHRNA7 protein mutant form affects the susceptibility to Dihydro-beta-Erythroidine Dihydro-beta-Erythroidine binds to and results in decreased activity of CHRNA7 protein |
CTD |
PMID:10082212 PMID:19448648 |
|
NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO EXP |
Carbachol inhibits the reaction [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine inhibits the reaction [1-Butanol binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine inhibits the reaction [[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased uptake of Calcium]; Dihydro-beta-Erythroidine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] dihydro-beta-erythroidine affects binding to Chrnb2 protein; dihydro-beta-erythroidine inhibits the reaction [epibatidine affects binding to Chrnb2 protein] in rat retina dihydro-beta-erythroidine affects binding to Chrnb2 protein; dihydro-beta-erythroidine competes with [Epibatidine binds to Chrnb2 protein] Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine inhibits the reaction [3-(2-(pyrrolidinyl)methoxy)pyridine analog results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in decreased susceptibility to Nicotine; Dihydro-beta-Erythroidine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine inhibits the reaction [[pozanicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in increased secretion of Acetylcholine]; Dihydro-beta-Erythroidine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] |
CTD RGD |
PMID:10945867 PMID:11600638 PMID:12604691 PMID:14645658 PMID:16569710 PMID:16915382 PMID:18385335 PMID:19047205 PMID:20100906 PMID:21715663 PMID:16129735 PMID:15016836 More...
|
RGD:2303195, RGD:2303194 |
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Chrnb3 |
cholinergic receptor nicotinic beta 3 subunit |
multiple interactions |
EXP |
dihydro-beta-erythroidine affects binding to Chrnb3 protein; dihydro-beta-erythroidine inhibits the reaction [epibatidine affects binding to Chrnb3 protein] in rat retina |
RGD |
PMID:16129735 |
RGD:2303195 |
NCBI chr16:64,713,438...64,751,360
Ensembl chr16:64,714,169...64,751,360
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
affects binding multiple interactions |
EXP |
[CHRNA4 protein binds to CHRNB4 protein] which binds to Dihydro-beta-Erythroidine Dihydro-beta-Erythroidine results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein] |
CTD |
PMID:9687574 |
|
NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[Mecamylamine co-treated with Dihydro-beta-Erythroidine co-treated with Bungarotoxins] inhibits the reaction [Nicotine results in increased expression of CXCR4 protein] |
CTD |
PMID:20457658 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
EXP |
Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in decreased expression of DNMT1 mRNA] |
CTD |
PMID:28555334 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
EXP |
Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in increased expression of GAD1 mRNA] |
CTD |
PMID:28555334 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions |
EXP |
Dihydro-beta-Erythroidine affects the reaction [Nicotine results in decreased activity of SLC6A3 protein] |
CTD |
PMID:23999947 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
EXP |
Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in increased expression of TNFRSF11B mRNA] |
CTD |
PMID:29981921 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
EXP |
Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in decreased expression of TNFSF11 mRNA] |
CTD |
PMID:29981921 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression increases localization multiple interactions |
ISO |
domoic acid results in increased expression of BAX mRNA domoic acid results in increased localization of BAX protein Carbachol inhibits the reaction [domoic acid results in increased localization of BAX protein] |
CTD |
PMID:18293405 PMID:19200344 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects expression |
ISO |
domoic acid affects the expression of BCL2 mRNA |
CTD |
PMID:18293405 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Carbachol inhibits the reaction [domoic acid results in increased activity of CASP3 protein] |
CTD |
PMID:19200344 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
domoic acid results in increased expression of GCLC mRNA; domoic acid results in increased expression of GCLC protein |
CTD |
PMID:23315585 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression decreases response to substance affects response to substance |
ISO |
domoic acid results in increased expression of GCLM mRNA; domoic acid results in increased expression of GCLM protein [GCLM protein results in decreased susceptibility to domoic acid] which results in decreased susceptibility to 2,3-dimethoxy-1,4-naphthoquinone; [GCLM protein results in decreased susceptibility to domoic acid] which results in decreased susceptibility to Hydrogen Peroxide; GCLM protein results in decreased susceptibility to domoic acid; GCLM results in decreased susceptibility to domoic acid GCLM affects the susceptibility to domoic acid |
CTD |
PMID:17804861 PMID:19200344 PMID:23315585 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
increases phosphorylation |
EXP |
domoic acid results in increased phosphorylation of GRIA1 protein |
CTD |
PMID:19564213 |
|
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Pvalb |
parvalbumin |
increases expression |
ISO |
domoic acid results in increased expression of PVALB protein |
CTD |
PMID:26797589 |
|
NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561
|
|
G |
Wdr35 |
WD repeat domain 35 |
increases expression multiple interactions |
EXP |
domoic acid results in increased expression of WDR35 mRNA; domoic acid results in increased expression of WDR35 protein 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline inhibits the reaction [domoic acid results in increased expression of WDR35 protein]; Edaravone inhibits the reaction [domoic acid results in increased expression of WDR35 protein] |
CTD |
PMID:23289926 |
|
NCBI chr 6:31,771,315...31,831,450
Ensembl chr 6:31,771,360...31,831,029
|
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding |
ISO |
glycycoumarin binds to PPARG protein |
CTD |
PMID:14608046 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity multiple interactions |
ISO |
Midazolam results in decreased activity of ABCB11 protein Midazolam inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:20829430 PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
Midazolam results in increased expression of ABCB1 protein |
CTD |
PMID:8632764 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
multiple interactions decreases metabolic processing |
ISO |
[ABCB6 gene mutant form results in decreased expression of CYP3A11 mRNA] inhibits the reaction [CYP3A11 protein results in increased metabolism of Midazolam]; [ABCB6 gene mutant form results in decreased expression of CYP3A11 protein] inhibits the reaction [CYP3A11 protein results in increased metabolism of Midazolam] ABCB6 gene mutant form results in decreased metabolism of Midazolam |
CTD |
PMID:25623066 |
|
NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
EXP |
Midazolam results in increased expression of BCL2 |
CTD |
PMID:17715682 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Midazolam results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Midazolam results in decreased activity of CYP1B1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
decreases activity |
ISO |
Midazolam results in decreased activity of CYP2A4 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Midazolam results in decreased activity of CYP2B10 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2c66 |
cytochrome P450, family 2, subfamily c, polypeptide 66 |
decreases activity |
ISO |
Midazolam results in decreased activity of CYP2C9 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:237,078,517...237,169,841
Ensembl chr 1:237,078,517...237,169,650
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
Midazolam results in decreased activity of CYP2C29 protein |
CTD |
PMID:18420780 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
Midazolam results in decreased activity of CYP2D6 protein |
CTD |
PMID:18420780 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases metabolic processing |
ISO |
CYP2E1 protein results in increased metabolism of Midazolam |
CTD |
PMID:17590308 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases hydroxylation increases glucuronidation affects metabolic processing decreases abundance increases metabolic processing increases expression increases oxidation multiple interactions |
EXP ISO |
CYP3A2 protein results in increased hydroxylation of Midazolam CYP3A4 protein results in increased glucuronidation of Midazolam CYP3A4 gene polymorphism affects the metabolism of Midazolam; CYP3A4 protein affects the metabolism of Midazolam CYP3A4 protein results in decreased abundance of Midazolam CYP3A4 protein results in increased metabolism of Midazolam CYP3A4 protein results in increased hydroxylation of Midazolam Midazolam results in increased expression of CYP3A4 mRNA CYP3A4 protein results in increased oxidation of Midazolam [3-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [5-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [6-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [6-methylflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [7-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [[3-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[5-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[6-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[6-methylflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[7-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[alpha-naphthoflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[artemetin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[beta-Naphthoflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[chrysin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[eupatilin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[flavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[galangin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[nobiletin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[sinensetin analog results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[sinensetin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[tangeretin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [alpha-naphthoflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [artemetin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [beta-Naphthoflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [Carbamazepine results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; [chrysin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased abundance of 1-hydroxymethylmidazolam; [CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased abundance of 4-hydroxymidazolam; [CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam; [Dexamethasone results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; [eupatilin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [flavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [galangin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [Ketoconazole results in decreased activity of CYP3A4 protein] which results in decreased hydroxylation of Midazolam; [Ketoconazole results in decreased activity of CYP3A4 protein] which results in decreased metabolism of Midazolam; [L 754394 results in decreased activity of CYP3A4 protein] which results in decreased hydroxylation of Midazolam; [nobiletin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [Pioglitazone results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; [sinensetin analog results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [sinensetin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [tangeretin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; acacetin inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; acacetin promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; allyl methyl disulfide inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Amiodarone inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Apigenin inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; Apigenin promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Atorvastatin inhibits the reaction [CYP3A4 protein affects the metabolism of Midazolam]; bufalin promotes the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; bufogenin promotes the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; caryophyllene inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; cinobufagin promotes the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; citral inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Curcumin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased hydroxylation of Midazolam]; deoxyelephantopin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Diltiazem inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Eucalyptol inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; flavanone inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; flavanone promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; flavone inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; flavone promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Fluvastatin inhibits the reaction [CYP3A4 protein affects the metabolism of Midazolam]; fructus schizandrae, radix ginseng, radix ophiopogonis drug combination affects the reaction [CYP3A4 protein affects the metabolism of Midazolam]; Fusidic Acid inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; galangin inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; galangin promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; gingerol inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in decreased abundance of Midazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; Limonene inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Midazolam inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Midazolam inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Midazolam inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]; Mifepristone inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Mifepristone inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; muscone promotes the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; Oleanolic Acid inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; Pantoprazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; potassium ferricyanide inhibits the reaction [Diltiazem inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; potassium ferricyanide promotes the reaction [Diltiazem inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; rabeprazole-thioether inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; shexiang baoxin promotes the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; Verapamil inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; YM 758 inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; zafirlukast inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam] shikonin inhibits the reaction [CYP3A2 protein results in increased hydroxylation of Midazolam] |
CTD |
PMID:8114683 PMID:10997946 PMID:11911841 PMID:12401345 PMID:12433797 PMID:12467917 PMID:12695342 PMID:15043991 PMID:15258107 PMID:15286053 PMID:15370959 PMID:15383492 PMID:15499178 PMID:15618748 PMID:15626586 PMID:15784650 PMID:15801540 PMID:15860655 PMID:15900284 PMID:15948934 PMID:16029222 PMID:16042670 PMID:16049126 PMID:16124035 PMID:17267297 PMID:17418993 PMID:17565714 PMID:17702393 PMID:18385293 PMID:19230594 PMID:19255940 PMID:19299527 PMID:19557931 PMID:20080160 PMID:20233841 PMID:21053930 PMID:21915887 PMID:22178124 PMID:22524704 PMID:22634058 PMID:22652334 PMID:23850985 PMID:23876819 PMID:25343516 PMID:26888941 PMID:26958860 PMID:27485346 PMID:28119166 PMID:28762043 PMID:28941798 PMID:29445054 PMID:30087611 PMID:31756459 PMID:34189909 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases hydroxylation |
EXP |
CYP3A23-3A1 protein results in increased hydroxylation of Midazolam |
CTD |
PMID:11911841 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects metabolic processing increases metabolic processing multiple interactions increases hydroxylation |
ISO EXP |
CYP3A5 gene polymorphism affects the metabolism of Midazolam; CYP3A5 protein affects the metabolism of Midazolam CYP3A5 protein results in increased metabolism of Midazolam [CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; erdafitinib inhibits the reaction [[CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; erdafitinib inhibits the reaction [CYP3A5 protein results in increased hydroxylation of Midazolam]; fructus schizandrae, radix ginseng, radix ophiopogonis drug combination affects the reaction [CYP3A5 protein affects the metabolism of Midazolam] |
CTD |
PMID:15383492 PMID:15499178 PMID:15801540 PMID:15900284 PMID:19557931 PMID:26958860 PMID:34189909 More...
|
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
increases expression |
ISO |
Midazolam results in increased expression of GABRA4 mRNA |
CTD |
PMID:16733821 |
|
NCBI chr14:36,590,782...36,667,724
Ensembl chr14:36,590,782...36,665,844
|
|
G |
Gabra6 |
gamma-aminobutyric acid type A receptor subunit alpha6 |
decreases response to substance |
ISO |
GABRA6 protein mutant form results in decreased susceptibility to Midazolam |
CTD |
PMID:12031754 |
|
NCBI chr10:26,810,411...26,825,768
Ensembl chr10:26,810,423...26,825,769
|
|
G |
Gabrb3 |
gamma-aminobutyric acid type A receptor subunit beta 3 |
increases response to substance |
ISO |
GABRB3 protein results in increased susceptibility to Midazolam |
CTD |
PMID:9523823 |
|
NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961
|
|
G |
Gabre |
gamma-aminobutyric acid type A receptor subunit epsilon |
decreases response to substance |
EXP |
GABRE protein results in decreased susceptibility to Midazolam |
CTD |
PMID:11691872 |
|
NCBI chr X:150,060,035...150,078,773
Ensembl chr X:150,060,040...150,078,693
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
affects response to substance affects binding |
ISO |
GABRG2 protein alternative form affects the susceptibility to Midazolam GABRG2 protein mutant form binds to Midazolam |
CTD |
PMID:10880692 |
|
NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346
|
|
G |
Gast |
gastrin |
multiple interactions |
EXP |
[fluanisone co-treated with Fentanyl co-treated with Midazolam] inhibits the reaction [GAST protein results in increased secretion of Histamine] |
CTD |
PMID:10864877 |
|
NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
affects response to substance |
ISO |
GRIN2A protein affects the susceptibility to Midazolam |
CTD |
PMID:15731593 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
[Midazolam cotreated with N-formyl-methionyl-leucyl-phenylalanine] decreases expression of ITGAM protein on neutrophils |
RGD |
PMID:20421794 |
RGD:329853762 |
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Midazolam results in increased activity of NR1I2 protein NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Midazolam] |
CTD |
PMID:18799805 PMID:20080160 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
decreases metabolic processing |
ISO |
NR1I3 gene mutant form results in decreased metabolism of Midazolam |
CTD |
PMID:27434302 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression |
ISO |
Midazolam results in increased expression of STAR protein |
CTD |
PMID:19857560 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Syn1 |
synapsin I |
decreases expression |
EXP |
Midazolam results in decreased expression of SYN1 protein |
CTD |
PMID:21920406 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Trh |
thyrotropin releasing hormone |
multiple interactions |
EXP |
Midazolam inhibits the reaction [TRH protein modified form binds to TRHR protein] |
CTD |
PMID:2845442 |
|
NCBI chr 4:124,742,111...124,777,094
Ensembl chr 4:124,742,111...124,744,637
|
|
G |
Trhr |
thyrotropin releasing hormone receptor |
multiple interactions |
EXP |
Midazolam inhibits the reaction [TRH protein modified form binds to TRHR protein] |
CTD |
PMID:2845442 |
|
NCBI chr 7:75,348,672...75,393,310
Ensembl chr 7:75,348,672...75,393,309
|
|
G |
Tspo |
translocator protein |
increases expression multiple interactions affects binding |
ISO EXP |
Midazolam results in increased expression of TSPO protein [Ketamine co-treated with Midazolam co-treated with Valproic Acid] inhibits the reaction [[Sarin co-treated with [Atropine co-treated with trimethylene-bis(4-hydroxyiminomethylpyridinium)]] results in increased expression of TSPO protein] Midazolam binds to TSPO protein |
CTD |
PMID:7603229 PMID:19857560 PMID:33823148 |
|
NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450
|
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
CYP3A4 protein affects the reaction [nimetazepam results in increased activity of CASP3 protein] |
CTD |
PMID:19005028 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
CYP3A4 protein affects the reaction [nimetazepam results in increased activity of CASP7 protein] |
CTD |
PMID:19005028 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
CYP3A4 protein affects the reaction [nimetazepam results in increased activity of CASP3 protein]; CYP3A4 protein affects the reaction [nimetazepam results in increased activity of CASP7 protein]; CYP3A4 protein results in increased metabolism of and results in increased activity of nimetazepam |
CTD |
PMID:19005028 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
nimetazepam inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
decreases activity |
ISO |
Nitrazepam results in decreased activity of AKR1C1 protein |
CTD |
PMID:11995921 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
decreases activity |
ISO |
Nitrazepam results in decreased activity of AKR1C2 protein |
CTD |
PMID:11995921 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases activity |
ISO |
Nitrazepam results in decreased activity of AKR1C3 protein |
CTD |
PMID:11995921 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
CYP3A4 protein affects the reaction [Nitrazepam results in increased activity of CASP3 protein] |
CTD |
PMID:19005028 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
CYP3A4 protein affects the reaction [Nitrazepam results in increased activity of CASP7 protein] |
CTD |
PMID:19005028 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
CYP3A4 protein affects the reaction [Nitrazepam results in increased activity of CASP3 protein]; CYP3A4 protein affects the reaction [Nitrazepam results in increased activity of CASP7 protein]; CYP3A4 protein results in increased metabolism of and results in increased activity of Nitrazepam |
CTD |
PMID:19005028 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Nitrazepam binds to and results in increased activity of ESR1 protein |
CTD |
PMID:25752796 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
increases expression |
EXP |
Nitroglycerin results in increased expression of ACAT1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Actb |
actin, beta |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of ACTB mRNA |
CTD |
PMID:12102619 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions decreases activity increases response to substance decreases expression affects metabolic processing affects response to substance |
ISO EXP |
[1-aminocyclopropanol analog results in decreased activity of ALDH2 protein] which results in decreased metabolism of Nitroglycerin; [Chloral Hydrate results in decreased activity of ALDH2 protein] which results in decreased metabolism of Nitroglycerin; [Cyanamide results in decreased activity of ALDH2 protein] which results in decreased metabolism of Nitroglycerin; Acetylcysteine inhibits the reaction [Nitroglycerin results in decreased activity of ALDH2 protein]; ALDH2 protein affects the reaction [Nitroglycerin results in decreased abundance of Cyclic GMP] ALDH2 protein affects the reaction [Ascorbic Acid deficiency results in decreased susceptibility to Nitroglycerin] ALDH2 protein results in increased susceptibility to Nitroglycerin Nitroglycerin results in decreased expression of ALDH2 mRNA; Nitroglycerin results in decreased expression of ALDH2 protein ALDH2 protein affects the metabolism of and results in increased activity of Nitroglycerin; ALDH2 protein affects the reaction [Nitroglycerin results in increased abundance of Reactive Oxygen Species]; Hemin inhibits the reaction [Nitroglycerin results in decreased activity of ALDH2 protein] ALDH2 protein affects the metabolism of Nitroglycerin ALDH2 gene polymorphism affects the susceptibility to Nitroglycerin; ALDH2 protein affects the susceptibility to Nitroglycerin; ALDH2 protein polymorphism affects the susceptibility to Nitroglycerin |
CTD |
PMID:15331769 PMID:16440063 PMID:17092343 PMID:17493633 PMID:17541025 PMID:17585900 PMID:17967228 PMID:18272654 PMID:19576883 PMID:21156756 PMID:23194305 More...
|
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of ALOX15 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Ap2m1 |
adaptor related protein complex 2 subunit mu 1 |
increases expression |
EXP |
Nitroglycerin results in increased expression of AP2M1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr11:80,355,307...80,364,218
Ensembl chr11:80,328,041...80,364,140
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases expression |
EXP |
Nitroglycerin results in increased expression of APEX1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Apoa1 |
apolipoprotein A1 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of APOA1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Arl2 |
ADP-ribosylation factor like GTPase 2 |
increases expression |
EXP |
Nitroglycerin results in increased expression of ARL2 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:203,434,129...203,446,156
Ensembl chr 1:203,434,129...203,446,119
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of ATP5F1A mRNA |
CTD |
PMID:12102619 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
B2m |
beta-2 microglobulin |
affects expression |
ISO |
Nitroglycerin affects the expression of B2M protein |
CTD |
PMID:8350464 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
Bckdhb |
branched chain keto acid dehydrogenase E1 subunit beta |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of BCKDHB mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 8:84,845,264...85,027,812
Ensembl chr 8:84,845,264...85,027,812
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of BCL2 protein |
CTD |
PMID:17678976 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
C3 |
complement C3 |
increases expression |
ISO |
Nitroglycerin results in increased expression of C3 protein alternative form |
CTD |
PMID:10884648 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions increases expression affects expression |
EXP ISO |
Capsaicin inhibits the reaction [Nitroglycerin results in increased expression of CALCA mRNA]; Dexamethasone inhibits the reaction [Nitroglycerin results in increased expression of CALCA mRNA]; Ergotamine inhibits the reaction [Nitroglycerin results in increased expression of CALCA protein]; Methylene Blue inhibits the reaction [Nitroglycerin results in increased expression of CALCA mRNA]; NOS2 protein affects the reaction [Nitroglycerin results in increased expression of CALCA mRNA]; pimagedine inhibits the reaction [Nitroglycerin results in increased expression of CALCA mRNA]; Plant Oils inhibits the reaction [Nitroglycerin results in increased expression of CALCA protein] Nitroglycerin results in increased expression of CALCA mRNA; Nitroglycerin results in increased expression of CALCA protein Nitroglycerin affects the expression of CALCA protein |
CTD |
PMID:11919648 PMID:14659530 PMID:14729435 PMID:19121572 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calm2 |
calmodulin 2 |
increases expression |
EXP |
Nitroglycerin results in increased expression of CALM2 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287 Ensembl chr15:7,091,567...7,104,287
|
|
G |
Capn2 |
calpain 2 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of CAPN2 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
Nitroglycerin results in increased cleavage of and results in increased activity of CASP1 protein |
CTD |
PMID:12105852 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
decreases expression multiple interactions |
ISO |
Nitroglycerin results in decreased expression of CASP3 protein modified form Nitroglycerin results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:12105852 PMID:17322376 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Nitroglycerin results in increased expression of and results in increased activity of CAT protein |
CTD |
PMID:12860443 PMID:14732477 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cd3d |
CD3 delta subunit of T-cell receptor complex |
increases expression |
EXP |
Nitroglycerin results in increased expression of CD3D mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 8:45,287,803...45,293,342
Ensembl chr 8:45,288,749...45,301,809
|
|
G |
Cd5 |
Cd5 molecule |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of CD5 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:207,365,337...207,386,313
Ensembl chr 1:207,365,337...207,386,313
|
|
G |
Cd53 |
Cd53 molecule |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of CD53 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 2:194,352,139...194,399,668
Ensembl chr 2:194,352,139...194,399,657
|
|
G |
Cdc37 |
cell division cycle 37, HSP90 cochaperone |
increases expression |
EXP |
Nitroglycerin results in increased expression of CDC37 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
EXP |
Nitroglycerin results in increased expression of CDKN1B mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Celf2 |
CUGBP, Elav-like family member 2 |
increases expression |
EXP |
Nitroglycerin results in increased expression of CELF2 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr17:70,904,462...71,729,072
Ensembl chr17:71,210,853...71,728,333
|
|
G |
Ckb |
creatine kinase B |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of CKB mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Clu |
clusterin |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of CLU mRNA |
CTD |
PMID:12102619 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP |
Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein] |
CTD |
PMID:16775503 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cp |
ceruloplasmin |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of CP mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Crip2 |
cysteine-rich protein 2 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of CRIP2 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions decreases localization |
ISO |
4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [Nitroglycerin results in decreased localization of CTNNB1 protein]; 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [Nitroglycerin results in increased degradation of and results in decreased activity of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Nitroglycerin results in increased degradation of CTNNB1 protein]; Nitroglycerin inhibits the reaction [CTNNB1 protein binds to TCF4 protein]; Nitroglycerin results in decreased phosphorylation of and results in increased nitrosation of and results in increased degradation of and results in decreased activity of CTNNB1 protein; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Nitroglycerin inhibits the reaction [CTNNB1 protein binds to TCF4 protein]]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Nitroglycerin results in decreased localization of CTNNB1 protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Nitroglycerin results in increased degradation of and results in decreased activity of CTNNB1 protein] |
CTD |
PMID:17030184 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsd |
cathepsin D |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of CTSD mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions decreases expression increases expression decreases response to substance |
ISO EXP |
CYBB gene mutant form inhibits the reaction [Nitroglycerin results in decreased susceptibility to Acetylcholine]; Rosuvastatin Calcium inhibits the reaction [Nitroglycerin results in increased expression of CYBB mRNA] Nitroglycerin results in decreased expression of CYBB mRNA CYBB gene mutant form results in decreased susceptibility to Nitroglycerin |
CTD |
PMID:16633368 PMID:17493633 PMID:18522491 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects expression decreases expression |
EXP |
Vitamin E inhibits the reaction [nitroglycerine decreases Cyp1a2 protein expression in rat heart] nitroglycerin decreased expression of Cyp1a2 protein in thoracic aorta of rats |
RGD |
PMID:16520233 PMID:12688525 |
RGD:401900296, RGD:401900656 |
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b15 |
cytochrome P450, family 2, subfamily b, polypeptide 15 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of CYP2B15 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:82,094,188...82,106,492
Ensembl chr 1:82,094,180...82,106,492
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases expression |
EXP |
Nitroglycerin results in increased expression of CYP2E1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Defb5 |
defensin beta 5 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of DEFB4 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr16:70,612,985...70,615,389
Ensembl chr16:70,613,146...70,615,467
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of DHCR7 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
|
|
G |
Dyrk1a |
dual specificity tyrosine phosphorylation regulated kinase 1A |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of DYRK1A mRNA |
CTD |
PMID:12102619 |
|
NCBI chr11:33,890,706...34,009,420
Ensembl chr11:33,890,490...34,009,420
|
|
G |
Edn1 |
endothelin 1 |
decreases expression increases expression multiple interactions |
ISO EXP |
Nitroglycerin results in decreased expression of EDN1 mRNA Nitroglycerin results in increased expression of EDN1 protein Nitroglycerin results in decreased expression of EDN1 mRNA; Nitroglycerin results in decreased expression of EDN1 protein Losartan inhibits the reaction [Nitroglycerin results in increased expression of EDN1 protein] |
CTD |
PMID:11751199 PMID:12206003 PMID:12901495 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Elane |
elastase, neutrophil expressed |
increases expression |
ISO |
Nitroglycerin results in increased expression of ELANE protein |
CTD |
PMID:10884648 |
|
NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100
|
|
G |
Eln |
elastin |
increases expression |
EXP |
Nitroglycerin results in increased expression of ELN mRNA |
CTD |
PMID:12187120 |
|
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Faah |
fatty acid amide hydrolase |
increases activity multiple interactions |
EXP |
Nitroglycerin results in increased activity of FAAH protein Nitroglycerin promotes the reaction [FAAH protein results in increased chemical synthesis of Arachidonic Acid]; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide] |
CTD |
PMID:19515121 |
|
NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
Nitroglycerin results in increased expression of and results in increased localization of FAS protein |
CTD |
PMID:12105852 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
increases expression |
EXP |
Nitroglycerin results in increased expression of FGFR2 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of FMO1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO EXP |
Nitroglycerin results in increased expression of FOS protein anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; Ergotamine inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; Plant Oils inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; Pregabalin inhibits the reaction [Nitroglycerin results in increased expression of FOS protein] |
CTD |
PMID:7552308 PMID:10426492 PMID:16897600 PMID:18761334 PMID:19121572 PMID:19489890 PMID:19515121 PMID:25290014 More...
|
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gchfr |
GTP cyclohydrolase I feedback regulator |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of GCHFR mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 3:106,158,046...106,162,080
Ensembl chr 3:106,159,394...106,162,080
|
|
G |
Gnb3 |
G protein subunit beta 3 |
affects response to substance |
ISO |
GNB3 protein affects the susceptibility to Nitroglycerin |
CTD |
PMID:14586390 |
|
NCBI chr 4:157,639,468...157,645,171
Ensembl chr 4:157,639,469...157,645,173
|
|
G |
Gng7 |
G protein subunit gamma 7 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of GNG7 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 7:8,697,458...8,761,239
Ensembl chr 7:8,697,521...8,761,240
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases response to substance |
ISO |
GPX1 gene mutant form results in decreased susceptibility to Nitroglycerin |
CTD |
PMID:24296279 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Grk6 |
G protein-coupled receptor kinase 6 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of GRK6 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,177,019...9,192,644
|
|
G |
Grn |
granulin precursor |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of GRN mRNA |
CTD |
PMID:12102619 |
|
NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775
|
|
G |
Gsn |
gelsolin |
increases expression |
EXP |
Nitroglycerin results in increased expression of GSN mRNA |
CTD |
PMID:12187120 |
|
NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of GSTA2 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
affects metabolic processing |
EXP |
GSTA3 protein affects the metabolism of Nitroglycerin |
CTD |
PMID:8968379 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
affects metabolic processing |
EXP |
GSTM2 protein affects the metabolism of Nitroglycerin |
CTD |
PMID:8968379 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gtf3c1 |
general transcription factor IIIC subunit 1 |
increases expression |
EXP |
Nitroglycerin results in increased expression of GTF3C1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:180,203,995...180,270,201
Ensembl chr 1:180,203,995...180,270,201
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
increases expression |
EXP |
Nitroglycerin results in increased expression of GUCY1A1 mRNA; Nitroglycerin results in increased expression of GUCY1A1 protein |
CTD |
PMID:11331261 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
increases expression |
ISO EXP |
Nitroglycerin results in increased expression of GUCY1B1 protein Nitroglycerin results in increased expression of GUCY1B1 mRNA; Nitroglycerin results in increased expression of GUCY1B1 protein |
CTD |
PMID:11331261 PMID:11742226 PMID:17541025 |
|
NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Hbb |
hemoglobin subunit beta |
increases expression |
EXP |
Nitroglycerin results in increased expression of HBB mRNA |
CTD |
PMID:12187120 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hdc |
histidine decarboxylase |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of HDC mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 3:113,847,256...113,865,334
Ensembl chr 3:113,847,260...113,865,341
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Nitroglycerin results in increased expression of HMOX1 mRNA [Hemin co-treated with Nitroglycerin] results in increased expression of HMOX1 mRNA; [Hemin co-treated with Nitroglycerin] results in increased expression of HMOX1 protein |
CTD |
PMID:17092343 PMID:17470570 PMID:17541025 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hpn |
hepsin |
increases expression |
EXP |
Nitroglycerin results in increased expression of HPN mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:86,337,085...86,352,785
Ensembl chr 1:86,337,087...86,352,811
|
|
G |
Iapp |
islet amyloid polypeptide |
increases expression |
EXP |
Nitroglycerin results in increased expression of IAPP mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 4:175,237,107...175,244,373
Ensembl chr 4:175,237,115...175,242,920
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression |
EXP |
Nitroglycerin results in increased expression of ID2 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of IDO1 protein |
CTD |
PMID:28659861 |
|
NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
EXP |
Nitroglycerin results in increased expression of IL1B protein |
CTD |
PMID:11701602 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO EXP |
Nitroglycerin results in increased expression of IL6 mRNA; Nitroglycerin results in increased expression of IL6 protein |
CTD |
PMID:11701602 PMID:17470570 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jtb |
jumping translocation breakpoint |
increases expression |
EXP |
Nitroglycerin results in increased expression of JTB mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 2:175,685,392...175,689,609
Ensembl chr 2:175,684,993...175,690,108
|
|
G |
Kmo |
kynurenine 3-monooxygenase |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of KMO protein |
CTD |
PMID:28659861 |
|
NCBI chr13:87,557,080...87,589,334
Ensembl chr13:87,557,286...87,588,881
|
|
G |
Kng2 |
kininogen 2 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of KNG2 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr11:77,913,876...77,936,247
Ensembl chr11:77,909,612...78,002,971
|
|
G |
Kynu |
kynureninase |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of KYNU protein |
CTD |
PMID:28659861 |
|
NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488
|
|
G |
Maob |
monoamine oxidase B |
increases expression |
EXP |
Nitroglycerin results in increased expression of MAOB mRNA |
CTD |
PMID:12102619 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Mecr |
mitochondrial trans-2-enoyl-CoA reductase |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of MECR mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 5:144,029,684...144,056,373
Ensembl chr 5:144,029,731...144,055,863
|
|
G |
Mgll |
monoglyceride lipase |
multiple interactions increases activity |
EXP |
Nitroglycerin promotes the reaction [MGLL protein results in increased chemical synthesis of Glycerol]; Nitroglycerin promotes the reaction [MGLL protein results in increased degradation of 2-oleoylglycerol] Nitroglycerin results in increased activity of MGLL protein |
CTD |
PMID:19515121 |
|
NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression |
ISO |
Nitroglycerin results in increased expression of MMP2 mRNA |
CTD |
PMID:12084592 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp7 |
matrix metallopeptidase 7 |
increases expression |
ISO |
Nitroglycerin results in increased expression of MMP7 mRNA |
CTD |
PMID:12084592 |
|
NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases activity increases expression |
ISO |
Nitroglycerin results in increased activity of MMP9 protein Nitroglycerin results in increased expression of MMP9 mRNA |
CTD |
PMID:12084592 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
decreases activity |
EXP |
Nitroglycerin results in decreased activity of MPO protein |
CTD |
PMID:8869312 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mxi1 |
MAX interactor 1, dimerization protein |
increases expression |
EXP |
Nitroglycerin results in increased expression of MXI1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:252,323,303...252,383,681
|
|
G |
Myo9b |
myosin IXb |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of MYO9B mRNA |
CTD |
PMID:12102619 |
|
NCBI chr16:17,945,379...18,030,114
Ensembl chr16:17,945,448...18,030,126
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
increases expression |
EXP |
Nitroglycerin results in increased expression of NCAM1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
decreases response to substance multiple interactions |
ISO |
NCF1 gene mutant form results in decreased susceptibility to Nitroglycerin NCF1 gene mutant form inhibits the reaction [Nitroglycerin results in decreased susceptibility to Acetylcholine] |
CTD |
PMID:18522491 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ndufa5 |
NADH:ubiquinone oxidoreductase subunit A5 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of NDUFA5 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 4:52,997,327...53,005,685
Ensembl chr 4:52,995,546...53,005,598
|
|
G |
Nkx2-1 |
NK2 homeobox 1 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of NKX2-1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 6:73,996,601...74,001,483
Ensembl chr 6:73,996,601...73,999,791
|
|
G |
Nnat |
neuronatin |
increases expression |
EXP |
Nitroglycerin results in increased expression of NNAT mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 3:146,225,941...146,228,868
Ensembl chr 3:146,226,407...146,228,834
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions increases expression |
EXP |
acetylsalicylic acid lysinate inhibits the reaction [Nitroglycerin results in increased expression of NOS1 protein]; Sumatriptan inhibits the reaction [Nitroglycerin results in increased expression of NOS1 protein] |
CTD |
PMID:14510930 PMID:15154853 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression multiple interactions increases expression |
ISO EXP |
Nitroglycerin results in decreased expression of NOS2 mRNA NOS2 protein affects the reaction [Nitroglycerin results in increased expression of CALCA mRNA] Nitroglycerin results in increased expression of NOS2 mRNA; Nitroglycerin results in increased expression of NOS2 protein Nitroglycerin results in decreased expression of NOS2 protein |
CTD |
PMID:11701602 PMID:12206003 PMID:14729435 PMID:14732477 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases expression |
EXP |
[Nitroglycerin co-treated with Hemin] results in increased expression of NOS3 mRNA; Nitroglycerin promotes the reaction [[Calcimycin results in increased activity of NOS3 protein] which results in increased abundance of Superoxides] Nitroglycerin results in increased expression of NOS3 mRNA; Nitroglycerin results in increased expression of NOS3 protein |
CTD |
PMID:10625313 PMID:12860443 PMID:14732477 PMID:17541025 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nox1 |
NADPH oxidase 1 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of NOX1 mRNA |
CTD |
PMID:17493633 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nox4 |
NADPH oxidase 4 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of NOX4 mRNA |
CTD |
PMID:17493633 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Npy |
neuropeptide Y |
increases expression |
EXP |
Nitroglycerin results in increased expression of NPY protein |
CTD |
PMID:10426492 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Paics |
phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase |
increases expression |
EXP |
Nitroglycerin results in increased expression of PAICS mRNA |
CTD |
PMID:12102619 |
|
NCBI chr14:31,199,086...31,232,731
Ensembl chr14:31,173,541...31,232,635
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases expression |
ISO |
Nitroglycerin results in decreased expression of PARP1 protein alternative form |
CTD |
PMID:17322376 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcsk1n |
proprotein convertase subtilisin/kexin type 1 inhibitor |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of PCSK1N mRNA |
CTD |
PMID:12102619 |
|
NCBI chr X:14,580,036...14,583,478
Ensembl chr X:14,580,038...14,583,566
|
|
G |
Pde1a |
phosphodiesterase 1A |
increases expression multiple interactions |
EXP |
Nitroglycerin results in increased expression of PDE1A mRNA; Nitroglycerin results in increased expression of PDE1A protein PDE1A protein inhibits the reaction [Nitroglycerin results in increased abundance of Cyclic GMP] |
CTD |
PMID:11696475 |
|
NCBI chr 3:64,745,140...65,025,178
Ensembl chr 3:64,747,269...65,024,874
|
|
G |
Pde2a |
phosphodiesterase 2A |
increases expression |
EXP |
Nitroglycerin results in increased expression of PDE2A mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:155,823,590...155,915,434
Ensembl chr 1:155,813,180...155,915,434
|
|
G |
Pla2g1b |
phospholipase A2 group IB |
increases expression |
EXP |
Nitroglycerin results in increased expression of PLA2G1B mRNA |
CTD |
PMID:12102619 |
|
NCBI chr12:41,142,193...41,151,967
Ensembl chr12:41,142,200...41,153,226
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
increases expression |
EXP |
Nitroglycerin results in increased expression of PLAUR mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of PMP22 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Polr1b |
RNA polymerase I subunit B |
increases expression |
EXP |
Nitroglycerin results in increased expression of POLR1B mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 3:116,333,910...116,358,385
Ensembl chr 3:116,333,889...116,358,379
|
|
G |
Ppp2cb |
protein phosphatase 2 catalytic subunit beta |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of PPP2CB mRNA |
CTD |
PMID:12102619 |
|
NCBI chr16:58,558,119...58,579,325
Ensembl chr16:58,558,122...58,579,576
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of PRKG1 protein |
CTD |
PMID:11331261 |
|
NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Ptgds |
prostaglandin D2 synthase |
increases expression |
EXP |
Nitroglycerin results in increased expression of PTGDS mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:8,281,899...8,284,833
|
|
G |
Ptprr |
protein tyrosine phosphatase, receptor type, R |
increases expression |
EXP |
Nitroglycerin results in increased expression of PTPRR mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 7:51,662,595...51,929,605
Ensembl chr 7:51,662,595...51,929,603
|
|
G |
Rab40c |
Rab40c, member RAS oncogene family |
increases expression |
EXP |
Nitroglycerin results in increased expression of RAB40C mRNA |
CTD |
PMID:12187120 |
|
NCBI chr10:14,900,926...14,936,153
Ensembl chr10:14,900,929...14,936,557
|
|
G |
Reg3b |
regenerating family member 3 beta |
increases expression |
EXP |
Nitroglycerin results in increased expression of REG3B mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases localization multiple interactions |
EXP |
Nitroglycerin results in increased localization of RELA protein Atorvastatin inhibits the reaction [Nitroglycerin results in increased localization of RELA protein] |
CTD |
PMID:19733216 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
increases activity |
ISO |
Nitroglycerin results in increased activity of REN protein |
CTD |
PMID:9527094 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Rgs8 |
regulator of G-protein signaling 8 |
increases expression |
EXP |
Nitroglycerin results in increased expression of RGS8 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr13:65,804,703...65,848,955
Ensembl chr13:65,804,797...65,846,807
|
|
G |
Rheb |
Ras homolog, mTORC1 binding |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of RHEB mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 4:10,278,970...10,320,160
Ensembl chr 4:10,279,370...10,320,160
|
|
G |
Rpl6 |
ribosomal protein L6 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of RPL6 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr12:35,347,493...35,352,011
Ensembl chr12:35,347,497...35,351,921
|
|
G |
Rps3a |
ribosomal protein S3a |
increases expression |
EXP |
Nitroglycerin results in increased expression of RPS3A mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 2:171,524,685...171,529,054
Ensembl chr 2:171,524,500...171,529,055
|
|
G |
Scgb1a1 |
secretoglobin family 1A member 1 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of SCGB1A1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:205,977,060...205,980,610
Ensembl chr 1:205,977,060...205,980,610
|
|
G |
Sdc4 |
syndecan 4 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of SDC4 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580
|
|
G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of SERPINA3N mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433
|
|
G |
Shank2 |
SH3 and multiple ankyrin repeat domains 2 |
increases expression |
EXP |
Nitroglycerin results in increased expression of SHANK2 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:199,146,210...199,590,962
Ensembl chr 1:199,169,429...199,589,394
|
|
G |
Slc4a4 |
solute carrier family 4 member 4 |
increases expression |
EXP |
Nitroglycerin results in increased expression of SLC4A4 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr14:18,841,289...19,293,297
Ensembl chr14:18,845,159...19,272,883
|
|
G |
Snn |
stannin |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of SNN mRNA |
CTD |
PMID:12102619 |
|
NCBI chr10:4,572,933...4,581,606
Ensembl chr10:4,572,376...4,584,021
|
|
G |
Snrk |
SNF related kinase |
increases expression |
EXP |
Nitroglycerin results in increased expression of SNRK mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 8:121,779,704...121,833,949
Ensembl chr 8:121,793,302...121,832,323
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Nitroglycerin results in increased expression of and results in increased activity of SOD2 protein |
CTD |
PMID:12860443 PMID:14732477 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression |
EXP |
Nitroglycerin results in increased expression of STAT3 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Syk |
spleen associated tyrosine kinase |
increases expression |
EXP |
Nitroglycerin results in increased expression of SYK mRNA |
CTD |
PMID:12102619 |
|
NCBI chr17:12,604,615...12,678,437
Ensembl chr17:12,604,619...12,661,410
|
|
G |
Syn2 |
synapsin II |
increases expression |
EXP |
Nitroglycerin results in increased expression of SYN2 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 4:148,178,846...148,347,010
Ensembl chr 4:148,186,270...148,344,192
|
|
G |
Tac1 |
tachykinin, precursor 1 |
affects expression |
EXP |
Nitroglycerin affects the expression of TAC1 protein |
CTD |
PMID:18197882 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tcf4 |
transcription factor 4 |
multiple interactions |
ISO |
Nitroglycerin inhibits the reaction [CTNNB1 protein binds to TCF4 protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Nitroglycerin inhibits the reaction [CTNNB1 protein binds to TCF4 protein]] |
CTD |
PMID:17030184 |
|
NCBI chr18:62,941,739...63,288,126
Ensembl chr18:62,943,782...63,284,425
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of TDO2 protein |
CTD |
PMID:28659861 |
|
NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of THY1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659
|
|
G |
Tmpo |
thymopoietin |
increases expression |
EXP |
Nitroglycerin results in increased expression of TMPO mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 7:25,642,752...25,667,756
Ensembl chr 7:25,586,725...25,667,727
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
Nitroglycerin results in decreased expression of TNF protein Capsaicin inhibits the reaction [Nitroglycerin results in decreased expression of TNF protein]; Methylene Blue inhibits the reaction [Nitroglycerin results in decreased expression of TNF protein] |
CTD |
PMID:10884648 PMID:11744139 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf8 |
TNF receptor superfamily member 8 |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of TNFRSF8 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 5:157,123,183...157,168,421
Ensembl chr 5:157,123,185...157,168,421
|
|
G |
Umod |
uromodulin |
increases expression |
EXP |
Nitroglycerin results in increased expression of UMOD mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:173,816,341...173,829,681
Ensembl chr 1:173,816,339...173,830,302
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
multiple interactions increases phosphorylation decreases phosphorylation |
ISO EXP |
1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one inhibits the reaction [Nitroglycerin results in increased phosphorylation of VASP protein] Nitroglycerin results in decreased phosphorylation of VASP protein Benomyl inhibits the reaction [Nitroglycerin results in increased phosphorylation of VASP protein]; Hemin inhibits the reaction [Nitroglycerin results in decreased phosphorylation of VASP protein] |
CTD |
PMID:11331261 PMID:14551241 PMID:15331769 PMID:17541025 PMID:17868048 PMID:20129490 More...
|
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
G |
Vtn |
vitronectin |
increases expression |
EXP |
Nitroglycerin results in increased expression of VTN mRNA |
CTD |
PMID:12102619 |
|
NCBI chr10:63,394,732...63,397,812
Ensembl chr10:63,394,719...63,397,810
|
|
G |
Ywhaz |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta |
decreases expression |
EXP |
Nitroglycerin results in decreased expression of YWHAZ mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 7:67,941,353...67,963,651
Ensembl chr 7:67,940,017...67,963,668
|
|
|
G |
A1bgl1 |
alpha-1-B glycoprotein like 1 |
affects expression |
EXP |
Orphenadrine affects the expression of A1BGL1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:92,314,930...92,318,652
|
|
G |
A2m |
alpha-2-macroglobulin |
affects expression |
EXP |
Orphenadrine affects the expression of A2M mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
affects expression |
EXP |
Orphenadrine affects the expression of ABCB1B mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
[Orphenadrine co-treated with Diethylnitrosamine] results in increased expression of ABCC2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
affects expression |
EXP |
Orphenadrine affects the expression of ABCC3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcd2 |
ATP binding cassette subfamily D member 2 |
affects expression |
EXP |
Orphenadrine affects the expression of ABCD2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642
|
|
G |
Ablim3 |
actin binding LIM protein family, member 3 |
affects expression |
EXP |
Orphenadrine affects the expression of ABLIM3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:55,256,135...55,376,629
Ensembl chr18:55,257,583...55,376,380
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
affects expression |
EXP |
Orphenadrine affects the expression of ACE2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acer3 |
alkaline ceramidase 3 |
affects expression |
EXP |
Orphenadrine affects the expression of ACER3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:152,504,180...152,606,596
Ensembl chr 1:152,504,186...152,606,591
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
affects expression |
EXP |
Orphenadrine affects the expression of ACSL5 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
|
|
G |
Acsm3 |
acyl-CoA synthetase medium-chain family member 3 |
affects expression |
EXP |
Orphenadrine affects the expression of ACSM3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184
|
|
G |
Adgrg2 |
adhesion G protein-coupled receptor G2 |
affects expression |
EXP |
Orphenadrine affects the expression of ADGRG2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr X:34,297,402...34,422,590
Ensembl chr X:34,297,402...34,422,609
|
|
G |
Adgrv1 |
adhesion G protein-coupled receptor V1 |
affects expression |
EXP |
Orphenadrine affects the expression of ADGRV1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:11,331,434...11,911,713
Ensembl chr 2:11,331,442...11,911,688
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
affects expression |
EXP |
Orphenadrine affects the expression of ADH4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adora1 |
adenosine A1 receptor |
affects expression |
EXP |
Orphenadrine affects the expression of ADORA1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adora2a |
adenosine A2a receptor |
affects expression |
EXP |
Orphenadrine affects the expression of ADORA2A mRNA |
CTD |
PMID:23665939 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
affects expression |
EXP |
Orphenadrine affects the expression of ADRB2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Ajuba |
ajuba LIM protein |
affects expression |
EXP |
Orphenadrine affects the expression of JUB mRNA |
CTD |
PMID:23665939 |
|
NCBI chr15:28,019,775...28,031,537
Ensembl chr15:28,019,778...28,030,021
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
affects expression |
EXP |
Orphenadrine affects the expression of AKR7A3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
affects expression |
EXP |
Orphenadrine affects the expression of ALDH1A1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
affects expression |
EXP |
Orphenadrine affects the expression of ALPL mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Als2cl |
ALS2 C-terminal like |
affects expression |
EXP |
Orphenadrine affects the expression of ALS2CL mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:110,863,753...110,884,434
Ensembl chr 8:110,864,975...110,884,419
|
|
G |
Amigo3 |
adhesion molecule with Ig like domain 3 |
affects expression |
EXP |
Orphenadrine affects the expression of AMIGO3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:108,741,899...108,743,425
Ensembl chr 8:108,693,060...108,744,555
|
|
G |
Amotl2 |
angiomotin like 2 |
affects expression |
EXP |
Orphenadrine affects the expression of AMOTL2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:103,303,368...103,319,161
Ensembl chr 8:103,302,992...103,318,910
|
|
G |
Angptl4 |
angiopoietin-like 4 |
affects expression |
EXP |
Orphenadrine affects the expression of ANGPTL4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Angptl6 |
angiopoietin-like 6 |
affects expression |
EXP |
Orphenadrine affects the expression of ANGPTL6 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:19,413,617...19,419,925
Ensembl chr 8:19,413,619...19,419,925
|
|
G |
Ankrd9 |
ankyrin repeat domain 9 |
affects expression |
EXP |
Orphenadrine affects the expression of ANKRD9 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 6:130,001,914...130,008,792
Ensembl chr 6:129,998,486...130,008,923
|
|
G |
Ano1 |
anoctamin 1 |
affects expression |
EXP |
Orphenadrine affects the expression of ANO1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069
|
|
G |
Anxa5 |
annexin A5 |
affects expression |
EXP |
Orphenadrine affects the expression of ANXA5 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
App |
amyloid beta precursor protein |
affects expression |
EXP |
Orphenadrine affects the expression of APP mRNA |
CTD |
PMID:23665939 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp9 |
aquaporin 9 |
affects expression |
EXP |
Orphenadrine affects the expression of AQP9 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Arhgap10 |
Rho GTPase activating protein 10 |
affects expression |
EXP |
Orphenadrine affects the expression of ARHGAP10 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:30,448,572...30,710,315
Ensembl chr19:30,448,637...30,710,313
|
|
G |
Arhgap22 |
Rho GTPase activating protein 22 |
affects expression |
EXP |
Orphenadrine affects the expression of ARHGAP22 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:8,473,806...8,631,552
Ensembl chr16:8,476,306...8,631,548
|
|
G |
Arhgef10 |
Rho guanine nucleotide exchange factor 10 |
affects expression |
EXP |
Orphenadrine affects the expression of ARHGEF10 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:74,647,147...74,738,784
Ensembl chr16:74,647,153...74,738,173
|
|
G |
Arhgef15 |
Rho guanine nucleotide exchange factor 15 |
affects expression |
EXP |
Orphenadrine affects the expression of ARHGEF15 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:53,650,521...53,663,269
Ensembl chr10:53,650,553...53,663,913
|
|
G |
Armcx1 |
armadillo repeat containing, X-linked 1 |
affects expression |
EXP |
Orphenadrine affects the expression of ARMCX1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr X:97,898,969...97,902,874
Ensembl chr X:97,898,883...97,903,299
|
|
G |
Arrdc2 |
arrestin domain containing 2 |
affects expression |
EXP |
Orphenadrine affects the expression of ARRDC2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:18,601,897...18,606,029
Ensembl chr16:18,601,897...18,606,029
|
|
G |
Atf3 |
activating transcription factor 3 |
affects expression |
EXP |
Orphenadrine affects the expression of ATF3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp2b2 |
ATPase plasma membrane Ca2+ transporting 2 |
affects expression |
EXP |
Orphenadrine affects the expression of ATP2B2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:146,894,602...147,208,060
Ensembl chr 4:146,896,332...147,140,665
|
|
G |
Atrnl1 |
attractin like 1 |
affects expression |
EXP |
Orphenadrine affects the expression of ATRNL1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:256,670,976...257,219,291
Ensembl chr 1:256,670,627...257,213,197
|
|
G |
Azin2 |
antizyme inhibitor 2 |
affects expression |
EXP |
Orphenadrine affects the expression of AZIN2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:141,281,310...141,310,415
Ensembl chr 5:141,281,249...141,310,397
|
|
G |
B3gnt9 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9 |
affects expression |
EXP |
Orphenadrine affects the expression of B3GNT9 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:33,129,740...33,134,048
Ensembl chr19:33,128,142...33,132,344
|
|
G |
B4galt6 |
beta-1,4-galactosyltransferase 6 |
affects expression |
EXP |
Orphenadrine affects the expression of B4GALT6 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:11,958,382...12,015,247
Ensembl chr18:11,958,390...12,015,247
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
affects expression |
EXP |
Orphenadrine affects the expression of BAMBI mRNA |
CTD |
PMID:23665939 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
affects expression |
EXP |
Orphenadrine affects the expression of BBC3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl6 |
BCL6, transcription repressor |
affects expression |
EXP |
Orphenadrine affects the expression of BCL6 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bco2 |
beta-carotene oxygenase 2 |
affects expression |
EXP |
Orphenadrine affects the expression of BCO2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:50,882,174...50,907,676
Ensembl chr 8:50,882,181...50,915,467
|
|
G |
Bhlha15 |
basic helix-loop-helix family, member a15 |
affects expression |
EXP |
Orphenadrine affects the expression of BHLHA15 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr12:10,420,465...10,424,641
Ensembl chr12:10,420,467...10,424,713
|
|
G |
Bicc1 |
BicC family RNA binding protein 1 |
affects expression |
EXP |
Orphenadrine affects the expression of BICC1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr20:17,449,639...17,686,775
Ensembl chr20:17,449,560...17,686,776
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
affects expression |
EXP |
Orphenadrine affects the expression of BMP4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Btbd7 |
BTB domain containing 7 |
affects expression |
EXP |
Orphenadrine affects the expression of BTBD7 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 6:121,920,365...122,010,114
Ensembl chr 6:121,923,023...121,972,405
|
|
G |
C1h11orf24 |
similar to human chromosome 11 open reading frame 24 |
affects expression |
EXP |
Orphenadrine affects the expression of C1H11ORF24 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:200,945,188...200,953,953
Ensembl chr 1:200,945,180...200,962,585
|
|
G |
C1qtnf2 |
C1q and TNF related 2 |
affects expression |
EXP |
Orphenadrine affects the expression of C1QTNF2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:27,941,948...27,958,926
Ensembl chr10:27,941,948...27,959,185
|
|
G |
C8h15orf39 |
similar to human chromosome 15 open reading frame 39 |
affects expression |
EXP |
Orphenadrine affects the expression of C8H15ORF39 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:57,646,324...57,655,896
Ensembl chr 8:57,645,756...57,655,941
|
|
G |
Calcrl |
calcitonin receptor like receptor |
affects expression |
EXP |
Orphenadrine affects the expression of CALCRL mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:69,428,348...69,525,910
Ensembl chr 3:69,430,120...69,525,910
|
|
G |
Car1 |
carbonic anhydrase 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CA1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Car2 |
carbonic anhydrase 2 |
affects expression |
EXP |
Orphenadrine affects the expression of CA2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car3 |
carbonic anhydrase 3 |
affects expression |
EXP |
Orphenadrine affects the expression of CA3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Card19 |
caspase recruitment domain family, member 19 |
affects expression |
EXP |
Orphenadrine affects the expression of CARD19 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr17:15,432,632...15,445,317
Ensembl chr17:15,432,612...15,445,318
|
|
G |
Casp2 |
caspase 2 |
affects expression |
EXP |
Orphenadrine affects the expression of CASP2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Cblc |
Cbl proto-oncogene C |
affects expression |
EXP |
Orphenadrine affects the expression of CBLC mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:79,439,975...79,456,755
Ensembl chr 1:79,439,977...79,456,755
|
|
G |
Cbx4 |
chromobox 4 |
affects expression |
EXP |
Orphenadrine affects the expression of CBX4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:104,337,140...104,343,210
Ensembl chr10:104,336,876...104,356,706
|
|
G |
Ccdc68 |
coiled-coil domain containing 68 |
affects expression |
EXP |
Orphenadrine affects the expression of CCDC68 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:63,541,828...63,584,122
Ensembl chr18:63,541,896...63,584,119
|
|
G |
Ccn1 |
cellular communication network factor 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CCN1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP |
Orphenadrine promotes the reaction [Diethylnitrosamine results in increased expression of CCND1 mRNA] |
CTD |
PMID:23665939 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
affects expression |
EXP |
Orphenadrine affects the expression of CCND2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cd24 |
CD24 molecule |
affects expression |
EXP |
Orphenadrine affects the expression of CD24 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd276 |
Cd276 molecule |
affects expression |
EXP |
Orphenadrine affects the expression of CD276 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:58,937,751...58,968,082
Ensembl chr 8:58,937,751...58,968,380
|
|
G |
Cd36 |
CD36 molecule |
affects expression |
EXP |
Orphenadrine affects the expression of CD36 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdc42ep1 |
CDC42 effector protein 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CDC42EP1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:110,395,287...110,403,203
Ensembl chr 7:110,395,332...110,403,200
|
|
G |
Cdh3 |
cadherin 3 |
affects expression |
EXP |
Orphenadrine affects the expression of CDH3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084
|
|
G |
Cdr2 |
cerebellar degeneration-related protein 2 |
affects expression |
EXP |
Orphenadrine affects the expression of CDR2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:175,502,837...175,527,746
Ensembl chr 1:175,502,838...175,537,472
|
|
G |
Ces2h |
carboxylesterase 2H |
affects expression |
EXP |
Orphenadrine affects the expression of CES2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cfap68 |
cilia and flagella associated protein 68 |
affects expression |
EXP |
Orphenadrine affects the expression of CFAP68 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:51,107,663...51,113,192
Ensembl chr 8:51,107,721...51,113,420
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CGREF1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852
|
|
G |
Chmp4c |
charged multivesicular body protein 4C |
affects expression |
EXP |
Orphenadrine affects the expression of CHMP4C mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:91,391,729...91,428,652
Ensembl chr 2:91,388,530...91,428,668
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
affects expression |
EXP |
Orphenadrine affects the expression of CIDEA mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
affects expression |
EXP |
Orphenadrine affects the expression of CISH mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:107,972,306...107,977,254
Ensembl chr 8:107,972,306...107,977,250
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CLCF1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605
|
|
G |
Cldn23 |
claudin 23 |
affects expression |
EXP |
Orphenadrine affects the expression of CLDN23 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:56,413,677...56,415,401
Ensembl chr16:56,413,381...56,415,523
|
|
G |
Cndp1 |
carnosine dipeptidase 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CNDP1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:77,984,886...78,030,837
Ensembl chr18:77,984,907...78,007,765
|
|
G |
Col4a3 |
collagen type IV alpha 3 chain |
affects expression |
EXP |
Orphenadrine affects the expression of COL4A3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 9:83,875,849...84,004,955
Ensembl chr 9:83,875,561...84,001,895
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
affects expression |
EXP |
Orphenadrine affects the expression of CPT1B mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Crat |
carnitine O-acetyltransferase |
affects expression |
EXP |
Orphenadrine affects the expression of CRAT mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Crlf2 |
cytokine receptor-like factor 2 |
affects expression |
EXP |
Orphenadrine affects the expression of CRLF2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr14:103,943...108,643
Ensembl chr14:103,939...108,642
|
|
G |
Cryab |
crystallin, alpha B |
affects expression |
EXP |
Orphenadrine affects the expression of CRYAB mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Cryl1 |
crystallin, lambda 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CRYL1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr15:31,427,011...31,545,997
Ensembl chr15:31,427,054...31,545,997
|
|
G |
Csmd1 |
CUB and Sushi multiple domains 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CSMD1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:72,218,189...73,818,380
Ensembl chr16:72,218,503...73,817,614
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CSRNP1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183
|
|
G |
Cst9l |
cystatin 9-like |
affects expression |
EXP |
Orphenadrine affects the expression of CST9L mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:136,288,093...136,290,906
Ensembl chr 3:136,288,093...136,290,906
|
|
G |
Ctps1 |
CTP synthase 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CTPS1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G |
Ctrb1 |
chymotrypsinogen B1 |
affects expression |
EXP |
Orphenadrine affects the expression of CTRB mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:39,652,931...39,657,689
Ensembl chr19:39,652,933...39,657,688
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions affects expression |
EXP |
[Orphenadrine co-treated with Diethylnitrosamine] results in increased expression of CYP1A1 mRNA Orphenadrine affects the expression of CYP1A1 mRNA |
CTD |
PMID:23665939 PMID:23665940 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
ISO EXP |
Orphenadrine inhibits the reaction [CYP1A2 protein results in decreased ethylation of 7-ethoxy-4-trifluoromethylcoumarin]; Orphenadrine inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of 7-hydroxy-4-trifluoromethylcoumarin] Orphenadrine results in decreased activity of CYP1A2 protein Orphenadrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] |
CTD |
PMID:9241656 PMID:18493746 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b15 |
cytochrome P450, family 2, subfamily b, polypeptide 15 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP2B15 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:82,094,188...82,106,492
Ensembl chr 1:82,094,180...82,106,492
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
affects expression multiple interactions |
EXP |
Orphenadrine affects the expression of CYP2B2 mRNA [Orphenadrine co-treated with Phenobarbital] affects the expression of CYP2B2 mRNA |
CTD |
PMID:23665939 PMID:23665940 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions decreases activity |
ISO |
Orphenadrine inhibits the reaction [CYP2B6 protein results in decreased ethylation of 7-ethoxy-4-trifluoromethylcoumarin]; Orphenadrine inhibits the reaction [CYP2B6 protein results in increased chemical synthesis of 7-hydroxy-4-trifluoromethylcoumarin] Orphenadrine results in decreased activity of CYP2B6 protein |
CTD |
PMID:9241656 PMID:12464242 PMID:15306208 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c12 |
cytochrome P450, family 2, subfamily c, polypeptide 12 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP2C12 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:238,699,859...238,757,011
Ensembl chr 1:238,699,854...238,757,019
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP2C24 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions decreases activity |
ISO |
Orphenadrine inhibits the reaction [CYP2E1 protein results in decreased ethylation of 7-ethoxy-4-trifluoromethylcoumarin]; Orphenadrine inhibits the reaction [CYP2E1 protein results in increased chemical synthesis of 7-hydroxy-4-trifluoromethylcoumarin] Orphenadrine results in decreased activity of CYP2E1 protein |
CTD |
PMID:9241656 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP3A62 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr12:16,397,998...16,433,833
Ensembl chr12:16,397,998...16,433,833
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP4A1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4a8 |
cytochrome P450, family 4, subfamily a, polypeptide 8 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP4A8 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:128,702,130...128,733,476
Ensembl chr 5:128,702,131...128,733,476
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP4B1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348
|
|
G |
Cyp4f5 |
cytochrome P450, family 4, subfamily f, polypeptide 5 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP4F5 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:11,544,040...11,558,982
Ensembl chr 7:11,544,082...11,558,978
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP7A1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP8B1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Cystm1 |
cysteine-rich transmembrane module containing 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CYSTM1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:27,945,862...28,013,509
Ensembl chr18:27,951,653...28,013,510
|
|
G |
Cyyr1 |
cysteine and tyrosine rich 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CYYR1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr11:24,557,620...24,664,007
Ensembl chr11:24,515,316...24,663,961
|
|
G |
Dact2 |
dishevelled-binding antagonist of beta-catenin 2 |
affects expression |
EXP |
Orphenadrine affects the expression of DACT2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:55,181,023...55,191,026
Ensembl chr 1:55,181,024...55,191,096
|
|
G |
Defb36 |
defensin beta 36 |
affects expression |
EXP |
Orphenadrine affects the expression of DEFB36 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:141,078,001...141,086,832
Ensembl chr 3:141,086,058...141,086,728
|
|
G |
Dip2a |
disco-interacting protein 2 homolog A |
affects expression |
EXP |
Orphenadrine affects the expression of DIP2A mRNA |
CTD |
PMID:23665939 |
|
NCBI chr20:12,284,566...12,371,068
Ensembl chr20:12,284,654...12,370,217
|
|
G |
Dll1 |
delta like canonical Notch ligand 1 |
affects expression |
EXP |
Orphenadrine affects the expression of DLL1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:56,312,062...56,320,177
Ensembl chr 1:56,312,066...56,320,179
|
|
G |
Dnhd1 |
dynein heavy chain domain 1 |
affects expression |
EXP |
Orphenadrine affects the expression of DNHD1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:159,990,785...160,077,990
Ensembl chr 1:159,990,438...160,074,858
|
|
G |
Dpp6 |
dipeptidyl peptidase like 6 |
affects expression |
EXP |
Orphenadrine affects the expression of DPP6 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:7,589,386...8,508,666
Ensembl chr 4:7,591,009...8,508,532
|
|
G |
Dppa3l2 |
developmental pluripotency associated 3 like 2 |
affects expression |
EXP |
Orphenadrine affects the expression of DPPA3L2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr17:2,886,537...2,887,217
|
|
G |
Dram1 |
DNA-damage regulated autophagy modulator 1 |
affects expression |
EXP |
Orphenadrine affects the expression of DRAM1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:22,742,794...22,776,888
Ensembl chr 7:22,742,849...22,776,765
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
affects expression |
EXP |
Orphenadrine affects the expression of DUSP1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
affects expression |
EXP |
Orphenadrine affects the expression of DUSP10 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Dusp13b |
dual specificity phosphatase 13B |
affects expression |
EXP |
Orphenadrine affects the expression of DUSP13B mRNA |
CTD |
PMID:23665939 |
|
NCBI chr15:2,567,432...2,575,105
Ensembl chr15:2,533,547...2,575,539
|
|
G |
Dusp16 |
dual specificity phosphatase 16 |
affects expression |
EXP |
Orphenadrine affects the expression of DUSP16 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:167,546,780...167,630,173
Ensembl chr 4:167,548,155...167,629,980
|
|
G |
Dusp8 |
dual specificity phosphatase 8 |
affects expression |
EXP |
Orphenadrine affects the expression of DUSP8 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:197,167,392...197,184,285
Ensembl chr 1:197,169,422...197,182,921
|
|
G |
Eeig1 |
estrogen-induced osteoclastogenesis regulator 1 |
affects expression |
EXP |
Orphenadrine affects the expression of EEIG1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:15,822,441...15,854,651
Ensembl chr 3:15,823,144...15,854,643
|
|
G |
Eeig2 |
EEIG family member 2 |
affects expression |
EXP |
Orphenadrine affects the expression of EEIG2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:196,608,499...196,663,371
Ensembl chr 2:196,608,499...196,663,371
|
|
G |
Efemp1 |
EGF containing fibulin extracellular matrix protein 1 |
affects expression |
EXP |
Orphenadrine affects the expression of EFEMP1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
affects expression |
EXP |
Orphenadrine affects the expression of EGLN3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
|
|
G |
Egr1 |
early growth response 1 |
affects expression |
EXP |
Orphenadrine affects the expression of EGR1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Emilin1 |
elastin microfibril interfacer 1 |
affects expression |
EXP |
Orphenadrine affects the expression of EMILIN1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 6:25,455,974...25,463,713
Ensembl chr 6:25,445,298...25,463,698
|
|
G |
Epha2 |
Eph receptor A2 |
affects expression |
EXP |
Orphenadrine affects the expression of EPHA2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117
|
|
G |
Ephb4 |
EPH receptor B4 |
affects expression |
EXP |
Orphenadrine affects the expression of EPHB4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr12:19,326,411...19,351,667
Ensembl chr12:19,326,427...19,351,314
|
|
G |
Eri2 |
ERI1 exoribonuclease family member 2 |
affects expression |
EXP |
Orphenadrine affects the expression of ERI2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:174,140,831...174,168,757
Ensembl chr 1:174,141,993...174,168,665
|
|
G |
F8 |
coagulation factor VIII |
affects expression |
EXP |
Orphenadrine affects the expression of F8 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:140,848...172,330
Ensembl chr18:140,955...171,857
|
|
G |
Fam89a |
family with sequence similarity 89, member A |
affects expression |
EXP |
Orphenadrine affects the expression of FAM89A mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:52,710,002...52,722,630
Ensembl chr19:52,710,019...52,722,631
|
|
G |
Fbxo27 |
F-box protein 27 |
affects expression |
EXP |
Orphenadrine affects the expression of FBXO27 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:83,965,426...83,987,781
Ensembl chr 1:83,965,986...83,987,778
|
|
G |
Fer1l5 |
fer-1-like family member 5 |
affects expression |
EXP |
Orphenadrine affects the expression of FER1L5 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 9:38,605,835...38,661,869
Ensembl chr 9:38,607,843...38,660,425
|
|
G |
Fgd5 |
FYVE, RhoGEF and PH domain containing 5 |
affects expression |
EXP |
Orphenadrine affects the expression of FGD5 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:124,497,061...124,594,564
Ensembl chr 4:124,497,068...124,594,563
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
affects expression |
EXP |
Orphenadrine affects the expression of FLT1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Flt4 |
Fms related receptor tyrosine kinase 4 |
affects expression |
EXP |
Orphenadrine affects the expression of FLT4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:33,913,725...33,954,770
Ensembl chr10:33,913,608...33,954,770
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
affects expression |
EXP |
Orphenadrine affects the expression of FMO1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Fndc5 |
fibronectin type III domain containing 5 |
affects expression |
EXP |
Orphenadrine affects the expression of FNDC5 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:141,481,593...141,491,257
Ensembl chr 5:141,481,590...141,490,731
|
|
G |
Fst |
follistatin |
affects expression |
EXP |
Orphenadrine affects the expression of FST mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
affects expression |
EXP |
Orphenadrine affects the expression of GADD45G mRNA |
CTD |
PMID:23665939 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Gdf11 |
growth differentiation factor 11 |
affects expression |
EXP |
Orphenadrine affects the expression of GDF11 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:1,311,732...1,325,211
Ensembl chr 7:1,311,732...1,320,725
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
affects expression |
EXP |
Orphenadrine affects the expression of GGT1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Gimd1 |
GIMAP family P-loop NTPase domain containing 1 |
affects expression |
EXP |
Orphenadrine affects the expression of GIMD1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:221,103,878...221,138,559
Ensembl chr 2:221,103,878...221,138,553
|
|
G |
Gipc2 |
GIPC PDZ domain containing family, member 2 |
affects expression |
EXP |
Orphenadrine affects the expression of GIPC2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:241,030,764...241,110,236
Ensembl chr 2:241,030,770...241,110,236
|
|
G |
Gmip |
Gem-interacting protein |
affects expression |
EXP |
Orphenadrine affects the expression of GMIP mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:19,600,723...19,614,459
Ensembl chr16:19,600,723...19,614,027
|
|
G |
Gna14 |
G protein subunit alpha 14 |
affects expression |
EXP |
Orphenadrine affects the expression of GNA14 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423
|
|
G |
Gnai1 |
G protein subunit alpha i1 |
affects expression |
EXP |
Orphenadrine affects the expression of GNAI1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417
|
|
G |
Gpat3 |
glycerol-3-phosphate acyltransferase 3 |
affects expression |
EXP |
Orphenadrine affects the expression of GPAT3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
affects expression |
EXP |
Orphenadrine affects the expression of GPR17 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:23,576,232...23,583,153
Ensembl chr18:23,577,242...23,582,966
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
affects expression multiple interactions |
EXP |
Orphenadrine affects the expression of GPX2 mRNA [Orphenadrine co-treated with Diethylnitrosamine] results in increased expression of GPX2 mRNA; [Phenobarbital co-treated with Orphenadrine] affects the expression of GPX2 mRNA |
CTD |
PMID:23665939 PMID:23665940 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
affects expression |
EXP |
Orphenadrine affects the expression of GRIA3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096
|
|
G |
Grik5 |
glutamate ionotropic receptor kainate type subunit 5 |
affects expression |
EXP |
Orphenadrine affects the expression of GRIK5 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:80,605,878...80,667,896
Ensembl chr 1:80,605,892...80,667,125
|
|
G |
Gse1 |
Gse1 coiled-coil protein |
affects expression |
EXP |
Orphenadrine affects the expression of GSE1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:48,274,164...48,629,456
Ensembl chr19:48,274,127...48,629,458
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
affects expression |
EXP |
Orphenadrine affects the expression of GSTM4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions affects expression |
EXP |
[Orphenadrine co-treated with Diethylnitrosamine] results in increased expression of GSTM3 mRNA; [Phenobarbital co-treated with Orphenadrine] affects the expression of GSTM3 mRNA Orphenadrine affects the expression of GSTM3 mRNA |
CTD |
PMID:23665939 PMID:23665940 |
|
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
affects expression |
EXP |
Orphenadrine affects the expression of GSTP1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hal |
histidine ammonia lyase |
affects expression |
EXP |
Orphenadrine affects the expression of HAL mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:28,007,449...28,037,701
Ensembl chr 7:28,006,972...28,037,701
|
|
G |
Hebp2 |
heme binding protein 2 |
affects expression |
EXP |
Orphenadrine affects the expression of HEBP2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:13,194,982...13,201,777
Ensembl chr 1:13,194,982...13,201,777
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
affects expression |
EXP |
Orphenadrine affects the expression of HES1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hgf |
hepatocyte growth factor |
affects expression |
EXP |
Orphenadrine affects the expression of HGF mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hid1 |
HID1 domain containing |
affects expression |
EXP |
Orphenadrine affects the expression of HID1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:100,589,555...100,610,050
Ensembl chr10:100,589,555...100,610,041
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
affects expression |
EXP |
Orphenadrine affects the expression of HSPA1A mRNA |
CTD |
PMID:23665939 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
affects expression |
EXP |
Orphenadrine affects the expression of HSPA1B mRNA |
CTD |
PMID:23665939 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hycc1 |
hyccin PI4KA lipid kinase complex subunit 1 |
affects expression |
EXP |
Orphenadrine affects the expression of HYCC1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:11,132,224...11,239,120
Ensembl chr 4:11,132,385...11,239,113
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
affects expression |
EXP |
Orphenadrine affects the expression of ID1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Id3 |
inhibitor of DNA binding 3 |
affects expression |
EXP |
Orphenadrine affects the expression of ID3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349
|
|
G |
Ido2 |
indoleamine 2,3-dioxygenase 2 |
affects expression |
EXP |
Orphenadrine affects the expression of IDO2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:67,459,158...67,498,052
Ensembl chr16:67,459,190...67,496,324
|
|
G |
Ier5 |
immediate early response 5 |
affects expression |
EXP |
Orphenadrine affects the expression of IER5 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr13:67,270,134...67,272,226
Ensembl chr13:67,270,135...67,272,227
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
affects expression |
EXP |
Orphenadrine affects the expression of IGFBP1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Ihh |
Indian hedgehog signaling molecule |
affects expression |
EXP |
Orphenadrine affects the expression of IHH mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 9:76,504,315...76,510,532
Ensembl chr 9:76,504,315...76,510,532
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
affects expression |
EXP |
Orphenadrine affects the expression of IKBKG mRNA |
CTD |
PMID:23665939 |
|
NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499
|
|
G |
Il17rb |
interleukin 17 receptor B |
affects expression |
EXP |
Orphenadrine affects the expression of IL17RB mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:5,180,431...5,194,125
Ensembl chr16:5,180,432...5,194,125
|
|
G |
Il33 |
interleukin 33 |
affects expression |
EXP |
Orphenadrine affects the expression of IL33 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Inf2 |
inverted formin 2 |
affects expression |
EXP |
Orphenadrine affects the expression of INF2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 6:131,649,162...131,675,944
Ensembl chr 6:131,649,211...131,675,941
|
|
G |
Ip6k2 |
inositol hexakisphosphate kinase 2 |
affects expression |
EXP |
Orphenadrine affects the expression of IP6K2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:109,483,843...109,510,172
Ensembl chr 8:109,484,310...109,510,166
|
|
G |
Irf7 |
interferon regulatory factor 7 |
affects expression |
EXP |
Orphenadrine affects the expression of IRF7 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832
|
|
G |
Irx1 |
iroquois homeobox 1 |
affects expression |
EXP |
Orphenadrine affects the expression of IRX1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:31,294,615...31,300,444
Ensembl chr 1:31,294,615...31,300,444
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
affects expression |
EXP |
Orphenadrine affects the expression of ISG15 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435
|
|
G |
Itgb3 |
integrin subunit beta 3 |
affects expression |
EXP |
Orphenadrine affects the expression of ITGB3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
affects expression |
EXP |
Orphenadrine affects the expression of JUN mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
affects expression |
EXP |
Orphenadrine affects the expression of JUNB mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Ka11 |
type I keratin KA11 |
affects expression |
EXP |
Orphenadrine affects the expression of KA11 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:85,161,424...85,164,737
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Kank2 |
KN motif and ankyrin repeat domains 2 |
affects expression |
EXP |
Orphenadrine affects the expression of KANK2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:20,311,676...20,341,107
Ensembl chr 8:20,311,676...20,340,900
|
|
G |
Kcnj15 |
potassium inwardly-rectifying channel, subfamily J, member 15 |
affects expression |
EXP |
Orphenadrine affects the expression of KCNJ15 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr11:34,577,397...34,621,725
Ensembl chr11:34,577,363...34,621,952
|
|
G |
Kcnk5 |
potassium two pore domain channel subfamily K member 5 |
affects expression |
EXP |
Orphenadrine affects the expression of KCNK5 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr15:4,122,442...4,164,718
Ensembl chr15:4,122,442...4,164,718
|
|
G |
Klf10 |
KLF transcription factor 10 |
affects expression |
EXP |
Orphenadrine affects the expression of KLF10 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
|
|
G |
Klhl21 |
kelch-like family member 21 |
affects expression |
EXP |
Orphenadrine affects the expression of KLHL21 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:162,514,888...162,523,545
Ensembl chr 5:162,514,765...162,523,545
|
|
G |
Kmo |
kynurenine 3-monooxygenase |
affects expression |
EXP |
Orphenadrine affects the expression of KMO mRNA |
CTD |
PMID:23665939 |
|
NCBI chr13:87,557,080...87,589,334
Ensembl chr13:87,557,286...87,588,881
|
|
G |
Krt10 |
keratin 10 |
affects expression |
EXP |
Orphenadrine affects the expression of KRT10 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701
|
|
G |
Krt8 |
keratin 8 |
affects expression |
EXP |
Orphenadrine affects the expression of KRT8 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Lag3 |
lymphocyte activating 3 |
affects expression |
EXP |
Orphenadrine affects the expression of LAG3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:157,712,665...157,722,229
Ensembl chr 4:157,712,667...157,720,404
|
|
G |
Lekr1 |
leucine, glutamate and lysine rich 1 |
affects expression |
EXP |
Orphenadrine affects the expression of LEKR1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:149,889,615...150,061,167
Ensembl chr 2:149,891,106...150,060,469
|
|
G |
Lgals2 |
galectin 2 |
affects expression |
EXP |
Orphenadrine affects the expression of LGALS2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:110,403,171...110,410,046
Ensembl chr 7:110,403,173...110,404,802
|
|
G |
Lhx8 |
LIM homeobox 8 |
affects expression |
EXP |
Orphenadrine affects the expression of LHX8 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:243,244,958...243,269,624
Ensembl chr 2:243,244,961...243,269,416
|
|
G |
Lilrb4 |
leukocyte immunoglobulin like receptor B4 |
affects expression |
EXP |
Orphenadrine affects the expression of LILRB4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:69,805,020...69,810,628
Ensembl chr 1:69,805,250...69,810,660
|
|
G |
Lin7a |
lin-7 homolog A, crumbs cell polarity complex component |
affects expression |
EXP |
Orphenadrine affects the expression of LIN7A mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:42,586,704...42,742,609
Ensembl chr 7:42,586,719...42,730,550
|
|
G |
Lmod2 |
leiomodin 2 |
affects expression |
EXP |
Orphenadrine affects the expression of LMOD2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:53,067,428...53,075,124
Ensembl chr 4:53,067,428...53,075,120
|
|
G |
Loxl4 |
lysyl oxidase-like 4 |
affects expression |
EXP |
Orphenadrine affects the expression of LOXL4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:241,396,183...241,416,385
Ensembl chr 1:241,397,983...241,416,322
|
|
G |
Lpcat4 |
lysophosphatidylcholine acyltransferase 4 |
affects expression |
EXP |
Orphenadrine affects the expression of LPCAT4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:99,044,729...99,052,963
Ensembl chr 3:99,044,729...99,052,875
|
|
G |
Lpin2 |
lipin 2 |
affects expression |
EXP |
Orphenadrine affects the expression of LPIN2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 9:111,083,378...111,158,193
Ensembl chr 9:111,083,745...111,158,193
|
|
G |
Lpl |
lipoprotein lipase |
affects expression |
EXP |
Orphenadrine affects the expression of LPL mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrrn4 |
leucine rich repeat neuronal 4 |
affects expression |
EXP |
Orphenadrine affects the expression of LRRN4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:120,138,093...120,150,877
Ensembl chr 3:120,139,410...120,150,831
|
|
G |
Ltc4s |
leukotriene C4 synthase |
affects expression |
EXP |
Orphenadrine affects the expression of LTC4S mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651
|
|
G |
Mafb |
MAF bZIP transcription factor B |
affects expression |
EXP |
Orphenadrine affects the expression of MAFB mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031
|
|
G |
Magee1 |
MAGE family member E1 |
affects expression |
EXP |
Orphenadrine affects the expression of MAGEE1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr X:70,189,242...70,192,789
Ensembl chr X:70,189,187...70,192,810
|
|
G |
Map1s |
microtubule-associated protein 1S |
affects expression |
EXP |
Orphenadrine affects the expression of MAP1S mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:18,516,759...18,527,777
Ensembl chr16:18,517,574...18,527,988
|
|
G |
Map4k2 |
mitogen activated protein kinase kinase kinase kinase 2 |
affects expression |
EXP |
Orphenadrine affects the expression of MAP4K2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:203,645,098...203,660,782
Ensembl chr 1:203,645,153...203,660,331
|
|
G |
Map4k4 |
mitogen-activated protein kinase kinase kinase kinase 4 |
affects expression |
EXP |
Orphenadrine affects the expression of MAP4K4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698
|
|
G |
Mapk12 |
mitogen-activated protein kinase 12 |
affects expression |
EXP |
Orphenadrine affects the expression of MAPK12 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664
|
|
G |
Matn4 |
matrilin 4 |
affects expression |
EXP |
Orphenadrine affects the expression of MATN4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:153,120,605...153,135,628
Ensembl chr 3:153,120,632...153,135,865
|
|
G |
Mcam |
melanoma cell adhesion molecule |
affects expression |
EXP |
Orphenadrine affects the expression of MCAM mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571
|
|
G |
Metap1d |
methionyl aminopeptidase type 1D (mitochondrial) |
affects expression |
EXP |
Orphenadrine affects the expression of METAP1D mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:56,279,471...56,354,518
Ensembl chr 3:56,279,493...56,351,981
|
|
G |
Mex3b |
mex-3 RNA binding family member B |
affects expression |
EXP |
Orphenadrine affects the expression of MEX3B mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:136,855,130...136,859,365
Ensembl chr 1:136,855,130...136,859,354
|
|
G |
Mex3d |
mex-3 RNA binding family member D |
affects expression |
EXP |
Orphenadrine affects the expression of MEX3D mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:9,325,575...9,332,705
Ensembl chr 7:9,325,488...9,332,096
|
|
G |
Mfge8 |
milk fat globule EGF and factor V/VIII domain containing |
affects expression |
EXP |
Orphenadrine affects the expression of MFGE8 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:133,064,665...133,080,069
Ensembl chr 1:133,064,665...133,080,073
|
|
G |
Mid1 |
midline 1 |
affects expression |
EXP |
Orphenadrine affects the expression of MID1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr X:24,116,674...24,491,205
Ensembl chr X:24,120,293...24,248,353
|
|
G |
Mid1ip1 |
MID1 interacting protein 1 |
affects expression |
EXP |
Orphenadrine affects the expression of MID1IP1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr X:12,060,993...12,063,318
Ensembl chr X:12,060,883...12,065,774
|
|
G |
Midn |
midnolin |
affects expression |
EXP |
Orphenadrine affects the expression of MIDN mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:9,548,100...9,559,605
Ensembl chr 7:9,549,650...9,559,752
|
|
G |
Mknk2 |
MAPK interacting serine/threonine kinase 2 |
affects expression |
EXP |
Orphenadrine affects the expression of MKNK2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:9,039,771...9,050,832
Ensembl chr 7:9,039,728...9,050,827
|
|
G |
Mlxip |
MLX interacting protein |
affects expression |
EXP |
Orphenadrine affects the expression of MLXIP mRNA |
CTD |
PMID:23665939 |
|
NCBI chr12:33,128,524...33,192,300
Ensembl chr12:33,128,520...33,192,374
|
|
G |
Mmd |
monocyte to macrophage differentiation-associated |
affects expression |
EXP |
Orphenadrine affects the expression of MMD mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:75,073,278...75,101,528
Ensembl chr10:75,073,365...75,101,528
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
affects expression |
EXP |
Orphenadrine affects the expression of MMP12 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp15 |
matrix metallopeptidase 15 |
affects expression |
EXP |
Orphenadrine affects the expression of MMP15 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:9,663,449...9,684,943
Ensembl chr19:9,663,449...9,684,943
|
|
G |
Mras |
muscle RAS oncogene homolog |
affects expression |
EXP |
Orphenadrine affects the expression of MRAS mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:99,944,036...100,006,771
Ensembl chr 8:99,944,036...99,996,408
|
|
G |
Mroh2a |
maestro heat-like repeat family member 2A |
affects expression |
EXP |
Orphenadrine affects the expression of MROH2A mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 9:88,814,515...88,862,346
Ensembl chr 9:88,814,197...88,852,607
|
|
G |
Mst1r |
macrophage stimulating 1 receptor |
affects expression |
EXP |
Orphenadrine affects the expression of MST1R mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:108,596,100...108,611,441
Ensembl chr 8:108,597,299...108,612,455
|
|
G |
Mtmr7 |
myotubularin related protein 7 |
affects expression |
EXP |
Orphenadrine affects the expression of MTMR7 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:51,641,267...51,732,212
Ensembl chr16:51,641,190...51,732,182
|
|
G |
Mtss2 |
MTSS I-BAR domain containing 2 |
affects expression |
EXP |
Orphenadrine affects the expression of MTSS2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:38,692,793...38,714,575
Ensembl chr19:38,693,194...38,713,507
|
|
G |
Mx2 |
MX dynamin like GTPase 2 |
affects expression |
EXP |
Orphenadrine affects the expression of MX2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr11:36,905,698...36,936,308
Ensembl chr11:36,906,111...36,930,342
|
|
G |
Mybph |
myosin binding protein H |
affects expression |
EXP |
Orphenadrine affects the expression of MYBPH mRNA |
CTD |
PMID:23665939 |
|
NCBI chr13:45,653,156...45,660,893
Ensembl chr13:45,653,234...45,660,893
|
|
G |
Mypop |
Myb-related transcription factor, partner of profilin |
affects expression |
EXP |
Orphenadrine affects the expression of MYPOP mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:78,639,699...78,650,555
Ensembl chr 1:78,639,769...78,650,552
|
|
G |
Myrf |
myelin regulatory factor |
affects expression |
EXP |
Orphenadrine affects the expression of MYRF mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:206,854,175...206,886,276
Ensembl chr 1:206,854,175...206,886,157
|
|
G |
Nat8f2 |
N-acetyltransferase 8 (GCN5-related) family member 2 |
affects expression |
EXP |
Orphenadrine affects the expression of NAT8F2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:118,319,984...118,323,159
Ensembl chr 4:118,319,988...118,324,395
|
|
G |
Ncaph |
non-SMC condensin I complex, subunit H |
affects expression |
EXP |
Orphenadrine affects the expression of NCAPH mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:114,371,937...114,399,178
Ensembl chr 3:114,371,941...114,399,180
|
|
G |
Ncoa7 |
nuclear receptor coactivator 7 |
affects expression |
EXP |
Orphenadrine affects the expression of NCOA7 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:26,856,228...27,016,950
Ensembl chr 1:26,856,530...27,015,871
|
|
G |
Nefh |
neurofilament heavy chain |
affects expression |
EXP |
Orphenadrine affects the expression of NEFH mRNA |
CTD |
PMID:22954530 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Neurl3 |
neuralized E3 ubiquitin protein ligase 3 |
affects expression |
EXP |
Orphenadrine affects the expression of NEURL3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 9:38,494,486...38,503,352
Ensembl chr 9:38,494,489...38,502,649
|
|
G |
Nfkbiz |
NFKB inhibitor zeta |
affects expression |
EXP |
Orphenadrine affects the expression of NFKBIZ mRNA |
CTD |
PMID:23665939 |
|
NCBI chr11:44,782,676...44,810,722
Ensembl chr11:44,782,676...44,810,723
|
|
G |
Nhsl3 |
NHS like 3 |
affects expression |
EXP |
Orphenadrine affects the expression of RGD1561149 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:141,564,399...141,593,154
Ensembl chr 5:141,564,399...141,593,176
|
|
G |
Ninj2 |
ninjurin 2 |
affects expression |
EXP |
Orphenadrine affects the expression of NINJ2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:153,306,439...153,408,618
Ensembl chr 4:153,306,553...153,408,617
|
|
G |
Nipal2 |
NIPA-like domain containing 2 |
affects expression |
EXP |
Orphenadrine affects the expression of NIPAL2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:65,774,477...65,884,807
Ensembl chr 7:65,774,477...65,884,807
|
|
G |
Nlrc4 |
NLR family, CARD domain containing 4 |
affects expression |
EXP |
Orphenadrine affects the expression of NLRC4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 6:20,991,785...21,018,254
Ensembl chr 6:20,995,266...21,018,248
|
|
G |
Noct |
nocturnin |
affects expression |
EXP |
Orphenadrine affects the expression of NOCT mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400
|
|
G |
Nos1ap |
nitric oxide synthase 1 adaptor protein |
affects expression |
EXP |
Orphenadrine affects the expression of NOS1AP mRNA |
CTD |
PMID:23665939 |
|
NCBI chr13:82,547,799...82,820,999
Ensembl chr13:82,530,577...82,820,949
|
|
G |
Nos3 |
nitric oxide synthase 3 |
affects expression |
EXP |
Orphenadrine affects the expression of NOS3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Npy |
neuropeptide Y |
affects expression |
EXP |
Orphenadrine affects the expression of NPY mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
affects expression |
EXP |
Orphenadrine affects the expression of NR1D1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705
|
|
G |
Nrep |
neuronal regeneration related protein |
affects expression |
EXP |
Orphenadrine affects the expression of NREP mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591
|
|
G |
Nrg1 |
neuregulin 1 |
affects expression |
EXP |
Orphenadrine affects the expression of NRG1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884
|
| |